<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="review-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Molecules</journal-id><journal-id journal-id-type="iso-abbrev">Molecules</journal-id><journal-id journal-id-type="pmc-domain-id">3416</journal-id><journal-id journal-id-type="pmc-domain">molecules</journal-id><journal-id journal-id-type="publisher-id">molecules</journal-id><journal-title-group><journal-title>Molecules</journal-title></journal-title-group><issn pub-type="epub">1420-3049</issn><publisher><publisher-name>Multidisciplinary Digital Publishing Institute  (MDPI)</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12430217</article-id><article-id pub-id-type="pmcid-ver">PMC12430217.1</article-id><article-id pub-id-type="pmcaid">12430217</article-id><article-id pub-id-type="pmcaiid">12430217</article-id><article-id pub-id-type="doi">10.3390/molecules30173598</article-id><article-id pub-id-type="publisher-id">molecules-30-03598</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Occurrence, Properties, Applications and Analytics of Cytosine and Its Derivatives</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-5660-1735</contrib-id><name name-style="western"><surname>Kluska</surname><given-names initials="M">Mariusz</given-names></name><xref rid="af1-molecules-30-03598" ref-type="aff">1</xref><xref rid="c1-molecules-30-03598" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-9673-1761</contrib-id><name name-style="western"><surname>Jab&#322;o&#324;ska</surname><given-names initials="J">Joanna</given-names></name><xref rid="af1-molecules-30-03598" ref-type="aff">1</xref><xref rid="c1-molecules-30-03598" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-3102-983X</contrib-id><name name-style="western"><surname>Pruka&#322;a</surname><given-names initials="D">Dorota</given-names></name><xref rid="af2-molecules-30-03598" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Pruka&#322;a</surname><given-names initials="W">Wies&#322;aw</given-names></name><xref rid="af2-molecules-30-03598" ref-type="aff">2</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name name-style="western"><surname>Kuzuya</surname><given-names initials="A">Akinori</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-molecules-30-03598"><label>1</label>Faculty of Natural Sciences, University of Siedlce, 54 3-Maja Str., 08-110 Siedlce, Poland</aff><aff id="af2-molecules-30-03598"><label>2</label>Faculty of Chemistry, Adam Mickiewicz University, Uniwersytetu Poznanskiego 8, 61-614 Poznan, Poland; <email>dorota.prukala@amu.edu.pl</email> (D.P.); <email>wieslaw.prukala@amu.edu.pl</email> (W.P.)</aff><author-notes><corresp id="c1-molecules-30-03598"><label>*</label>Correspondence: <email>mariusz.kluska@uws.edu.pl</email> (M.K.); <email>joanna.jablonska@uws.edu.pl</email> (J.J.); Tel.: +48-256-431-083 (M.K.)</corresp></author-notes><pub-date pub-type="epub"><day>03</day><month>9</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>9</month><year>2025</year></pub-date><volume>30</volume><issue>17</issue><issue-id pub-id-type="pmc-issue-id">496502</issue-id><elocation-id>3598</elocation-id><history><date date-type="received"><day>31</day><month>7</month><year>2025</year></date><date date-type="rev-recd"><day>27</day><month>8</month><year>2025</year></date><date date-type="accepted"><day>01</day><month>9</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>03</day><month>09</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>13</day><month>09</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-09-13 11:25:14.803"><day>13</day><month>09</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; 2025 by the authors.</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="molecules-30-03598.pdf"/><abstract><p>Cytosine and its derivatives are an important research topic in the fields of bioorganic chemistry, molecular biology and medicine due to their key role in the structure and function of nucleic acids. The article provides a detailed overview of the natural occurrence of cytosine, its biosynthetic and degradation pathways in living organisms, as well as its physicochemical and chemical properties. Particular attention was paid to the biological activity and therapeutic applications of cytosine derivatives, including their use in cancer, antiviral and epigenetic therapy. The analytical section describes high-performance liquid chromatography techniques as a major tool for identifying and determining cytosine and its derivatives in biological samples. Examples of separation conditions, column selection, mobile phases and detection parameters for these compounds are presented. The article also provides chemical structures, graphs, comparative tables and an up-to-date review of the scientific literature, presenting a comprehensive overview of the topic, including biological, chemical and analytical aspects.</p></abstract><kwd-group><kwd>analytics</kwd><kwd>applications</kwd><kwd>biological activity</kwd><kwd>cytosine</kwd><kwd>cytosine derivatives</kwd></kwd-group><funding-group><award-group><funding-source>Ministry of Science and Higher Education</funding-source><award-id>142/B/23</award-id></award-group><funding-statement>Ministry of Science and Higher Education: number&#8212;142/B/23.</funding-statement></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="sec1-molecules-30-03598"><title>1. Introduction</title><p>Cytosine (C) is one of the four nitrogenous bases of nucleic acids, alongside adenine, guanine and thymine (in DNA) and uracil (in RNA) [<xref rid="B1-molecules-30-03598" ref-type="bibr">1</xref>,<xref rid="B2-molecules-30-03598" ref-type="bibr">2</xref>]. It was first isolated from calf thymus tissue in 1894 by Albrecht Kossel and Albert Neumann [<xref rid="B3-molecules-30-03598" ref-type="bibr">3</xref>]. Structurally, cytosine is a pyrimidine derivative with a heterocyclic, aromatic ring containing two functional groups: an amine group at position 4 and a carbonyl group (oxo group) at position 2 (<xref rid="molecules-30-03598-f001" ref-type="fig">Figure 1</xref>) [<xref rid="B4-molecules-30-03598" ref-type="bibr">4</xref>,<xref rid="B5-molecules-30-03598" ref-type="bibr">5</xref>].</p><p>In DNA, cytosine occurs as 2&#8242;-deoxycytidine (a nucleoside with deoxyribose), and in RNA as cytidine (a nucleoside with ribose). In both cases, it forms complementary pairs with guanine through three hydrogen bonds (in the Watson&#8211;Crick model) that stabilise the double helix structure. Cytosine therefore plays a fundamental role in the transmission of genetic information [<xref rid="B6-molecules-30-03598" ref-type="bibr">6</xref>,<xref rid="B7-molecules-30-03598" ref-type="bibr">7</xref>]. Importantly, it is chemically unstable&#8212;it undergoes spontaneous deamination to uracil [<xref rid="B8-molecules-30-03598" ref-type="bibr">8</xref>,<xref rid="B9-molecules-30-03598" ref-type="bibr">9</xref>]. This process, which occurs with measurable frequency in vivo, leads to the formation of abnormal bases (uracil in DNA) and can result in point mutations if not repaired by appropriate repair enzymes (e.g., DNA glycosylases that remove uracil). In living organisms, cytosine does not occur exclusively in its basic form. Its chemical modifications are common, the most biologically important of which is methylation at C5, leading to the formation of 5-methylcytosine, the so-called fifth base of DNA, which has important epigenetic functions in the regulation of gene expression [<xref rid="B10-molecules-30-03598" ref-type="bibr">10</xref>,<xref rid="B11-molecules-30-03598" ref-type="bibr">11</xref>]. Methylation of cytosine is widespread in both prokaryotes and eukaryotes, although the extent of this phenomenon varies considerably between species. For example, in mammals 70&#8211;80% of cytosines in the context of CpG dinucleotides are methylated, while in yeast or nematodes, DNA methylation is negligible or absent. The discovery of methylcytosine dates back to the early 20th century, as the compound was synthesised already in 1901 and isolated from DNA hydrolysates of <italic toggle="yes">Mycobacterium tuberculosis</italic> in 1925. Subsequent decades of research also revealed other cytosine derivatives in genetic material, including 5-hydroxymethylcytosine (present in the genomes of some bacteriophages and as an intermediate product of DNA demethylation in eukaryotes) or N<sup>4</sup>-methylcytosine found in bacterial DNA [<xref rid="B12-molecules-30-03598" ref-type="bibr">12</xref>,<xref rid="B13-molecules-30-03598" ref-type="bibr">13</xref>,<xref rid="B14-molecules-30-03598" ref-type="bibr">14</xref>].</p><p>The purpose of this paper was to review the current knowledge of cytosine and its derivatives, with particular emphasis on analysis using high-performance liquid chromatography (HPLC). The paper discusses the following issues: (1) the occurrence of cytosine and its derivatives in nature; (2) chemical and physicochemical properties of cytosine and its derivatives; (3) main areas of application of these compounds in biology, medicine and industry; and (4) analytical techniques used for their identification and quantification, illustrated by selected examples of research results.</p></sec><sec id="sec2-molecules-30-03598"><title>2. Occurrence of Cytosine and Its Derivatives in Living Organisms</title><p>Cytosine is a component of both DNA and RNA in all organisms. The content of cytosine (or more precisely, GC pairs) in nucleic acids is a species-specific trait and can vary significantly depending on the organism [<xref rid="B15-molecules-30-03598" ref-type="bibr">15</xref>,<xref rid="B16-molecules-30-03598" ref-type="bibr">16</xref>]. In addition of G:C base pairs in DNA, it has been observed the presence of C:C+ base pairs in C-rich oligonucleotides due to the formation of i-motif structures. The average cytosine content in DNA varies greatly between organisms: from about 10% of all nitrogenous bases (in the genome of the protozoan <italic toggle="yes">Plasmodium falciparum</italic>, which has a very low overall content of GC pairs ~20%) to more than 35% (in the genome of the bacterium <italic toggle="yes">Streptomyces coelicolor</italic>, with GC reaching ~72%). In higher organisms (e.g., humans), cytosine typically accounts for ~20% of all bases (the human genome has an average composition of ~41% GC), while in yeast it accounts for ~19%, and in the intestinal bacterium <italic toggle="yes">E. coli</italic> ~25% (<italic toggle="yes">E. coli</italic> genome~51% GC) [<xref rid="B17-molecules-30-03598" ref-type="bibr">17</xref>]. Such large differences result from evolutionarily determined preferences for base pair composition and affect the physical properties of DNA (e.g., the melting point of the helix). In RNA, the cytosine content is usually close to that of guanine, but it can be adjusted depending on the type and function of RNA. Cytosine occurs in RNA, among others, as a component of cytidine in mRNA, rRNA and tRNA [<xref rid="B18-molecules-30-03598" ref-type="bibr">18</xref>,<xref rid="B19-molecules-30-03598" ref-type="bibr">19</xref>]. Modified nucleosides that are cytosine derivatives, such as 5-methylcytidine or 5-hydroxymethylcytidine, are often found in tRNA, where they play a role in stabilising the structure of tRNA and regulating codon recognition.</p><p>Like all pyrimidine and purine bases, cytosine is unlikely to be found in cells in free form (a free heterocyclic compound). It is synthesised and utilised mainly in the form of nucleosides and nucleotides. The biosynthesis of the pyrimidine ring occurs through the stepwise construction of a skeleton from simple metabolites: glutamine, carbon dioxide and aspartate [<xref rid="B20-molecules-30-03598" ref-type="bibr">20</xref>,<xref rid="B21-molecules-30-03598" ref-type="bibr">21</xref>,<xref rid="B22-molecules-30-03598" ref-type="bibr">22</xref>,<xref rid="B23-molecules-30-03598" ref-type="bibr">23</xref>,<xref rid="B24-molecules-30-03598" ref-type="bibr">24</xref>,<xref rid="B25-molecules-30-03598" ref-type="bibr">25</xref>].</p></sec><sec id="sec3-molecules-30-03598"><title>3. Chemical and Physicochemical Properties of Cytosine</title><sec id="sec3dot1-molecules-30-03598"><title>3.1. Tautomerism of Cytosine</title><p>As a heterocyclic compound, cytosine occurs in several tautomeric forms [<xref rid="B26-molecules-30-03598" ref-type="bibr">26</xref>,<xref rid="B27-molecules-30-03598" ref-type="bibr">27</xref>,<xref rid="B28-molecules-30-03598" ref-type="bibr">28</xref>,<xref rid="B29-molecules-30-03598" ref-type="bibr">29</xref>], resulting from the shift of hydrogen atoms between nitrogen and oxygen atoms in the ring (<xref rid="molecules-30-03598-f002" ref-type="fig">Figure 2</xref>). Six tautomeric forms of cytosine have been identified, three of which (C1, C2, C3) represent the basic structures.</p><p>The predominant form under physiological conditions is the 4-amino-2-oxo (lactim) form, in which cytosine occurs as 4-aminopyrimidone (with an &#8211;NH<sub>2</sub> group at C4 and an =O group at C2). Alternative tautomers include the 4-imino-2-oxo form (where the proton from the amino group is shifted to the nitrogen of the ring, forming an =NH group at C4) and the enolic 2-hydroxy-4-amino form (with the proton shifted from N3 to the oxygen atom at position 2). <xref rid="molecules-30-03598-f003" ref-type="fig">Figure 3</xref> shows a simplified equilibrium diagram of cytosine tautomers.</p><p>Due to the favourable bond distribution and aromatic nature of the system, the keto-amino form is the most stable and accounts for the vast majority of cytosine molecules in solution. However, the presence of rarer tautomers is biologically important, as it can lead to abnormal base pairing (e.g., the rare imine tautomer of cytosine can erroneously pair with adenine instead of guanine, which sometimes causes point mutations during DNA replication). The phenomenon of cytosine tautomerism has been studied experimentally, including spectroscopically and crystallographically. As early as the 1970s, a preference for the lactim (hydroxy) form over the lactam (oxo) form was demonstrated. The presence of substituents on the pyrimidine ring can alter the equilibrium of tautomers&#8212;for example, fluorine at position 5 (as in 5-fluorocytosine) strongly stabilises the lactim form, while the substitution of more electron-donor groups can favour oxo tautomers. The most abundant tautomeric form of cytosine under physiological conditions is lactim [<xref rid="B29-molecules-30-03598" ref-type="bibr">29</xref>].</p></sec><sec id="sec3dot2-molecules-30-03598"><title>3.2. Acid-Base Properties</title><p>Cytosine exhibits amphoteric properties [<xref rid="B30-molecules-30-03598" ref-type="bibr">30</xref>,<xref rid="B31-molecules-30-03598" ref-type="bibr">31</xref>]&#8212;it contains both nitrogen atoms capable of protonation (acting as a Br&#246;nsted base) and an &#8211;NH<sub>2</sub> group capable of deprotonation under strongly basic conditions (acting as an acid). There are two degrees of cytosine ionisation in aqueous solution [<xref rid="B32-molecules-30-03598" ref-type="bibr">32</xref>]. The first corresponds to the protonation of the N3 atom (a cytosine ion&#8212;cation&#8212;is formed), with an acidic equilibrium of pKa1&#8776;4.6. This means that at pH below ~4, most of the cytosine molecules are in the cationic (protonated) form, while at neutral pH, the neutral form (non-ionised lactim form of cytosine) predominates. The second degree of dissociation (pKa2&#8776;12.2) is associated with the dissociation of the proton from the 4-NH<sub>2</sub> group, which occurs under highly alkaline conditions. Above pH~12, only a portion of the molecules take on the anionic (4-amide) form [<xref rid="B33-molecules-30-03598" ref-type="bibr">33</xref>]. Under physiological conditions (pH~7), cytosine occurs almost exclusively as a neutral molecule, which is important for base pairing in DNA, as only this form forms correct pairs with guanine. The substitution of electronically active groups affects the acid-base properties of cytosine. For example, 5-fluorocytosine (5-FC) is a much stronger base, because the fluorine substituent reduces pKa1 to about 3.3, which means that 5-FC protonates less readily in aqueous solution (even at slightly acidic pH). At the same time, the electronic effect of fluorine reduces the basicity of the amine group 4-NH<sub>2</sub>, resulting in almost impossible deprotonation of this group (as in uracil, of which 5-FC is an analogue, there is virtually no proton abstraction&#8212;the NH group at position 3 of uracil is weakly acidic, pKa~8&#8211;9 for 5-FU). The introduction of other substituents (e.g., alkyl groups) generally raises the pKa of the first protonation (making the molecule a stronger base) through an inductive effect; for example, methylation at position 5 slightly increases the basicity of the ring. Knowledge of these parameters is important, among other things, for chromatographic separation conditions, as retention on columns depends on the degree of ionisation of the analytes.</p></sec><sec id="sec3dot3-molecules-30-03598"><title>3.3. Solubility and Physical Properties</title><p>Cytosine, as a pyrimidine base, is a moderately polar compound [<xref rid="B34-molecules-30-03598" ref-type="bibr">34</xref>]. One molecule contains three heteroatoms (one oxygen atom and two nitrogen atoms) capable of hydrogen bonds and one new amide group, hence cytosine forms strong hydrogen bonds in the crystal lattice and has a relatively high melting point. In its crystalline form, cytosine forms colourless, shiny plates. It crystallises from water as a monohydrate, losing its hydration water at 100 &#176;C, darkens above 300 &#176;C and decomposes at 320&#8211;325 &#176;C. The solubility of cytosine in water at room temperature is limited&#8212;1 g dissolves in approx. 130 mL of water (corresponding to ~7&#8211;8 mg/mL, or 0.77% <italic toggle="yes">m</italic>/<italic toggle="yes">v</italic>). It can therefore be classified as a compound that is slightly soluble in water. It is practically insoluble in non-polar solvents (e.g., diethyl ether), while it is slightly soluble in lower alcohols (e.g., methanol, ethanol). In aqueous solutions with acidic pH, its solubility increases due to ionisation (the cationic form is better solvated), although at the same time, in strongly acidic environments, slow hydrolysis of the N3-C4 bond can occur (under conditions of concentrated sulphuric acid(VI), cytosine may undergo depurination to uracil) [<xref rid="B35-molecules-30-03598" ref-type="bibr">35</xref>,<xref rid="B36-molecules-30-03598" ref-type="bibr">36</xref>,<xref rid="B37-molecules-30-03598" ref-type="bibr">37</xref>,<xref rid="B38-molecules-30-03598" ref-type="bibr">38</xref>]. Cytosine forms salts in reaction with strong acids&#8212;for example, with HCl it forms hydrochloride (i.a. crystalline cytosine 5-hydrochloride). In reaction with sodium hypochlorite in the presence of ammonia, cytosine produces a characteristic red colour, which historically was one of the methods used to detect it.</p><p>The substitution of a cytosine ring significantly affects solubility [<xref rid="B39-molecules-30-03598" ref-type="bibr">39</xref>,<xref rid="B40-molecules-30-03598" ref-type="bibr">40</xref>,<xref rid="B41-molecules-30-03598" ref-type="bibr">41</xref>]. The general trend is that the introduction of polar groups (e.g., &#8211;OH in 5-hydroxymethylcytosine or phosphate in cytidine nucleotides) increases hydrophilicity and solubility in water, while the substitution of non-polar groups (e.g., a methylene group in 5-methylcytosine) decreases solubility. For example, 5-fluorocytosine is more soluble in water than cytosine (about 1.5 g/100 mL, or 15 mg/mL at 25 &#176;C), which facilitates its pharmacological use in the form of oral and intravenous solutions [<xref rid="B42-molecules-30-03598" ref-type="bibr">42</xref>,<xref rid="B43-molecules-30-03598" ref-type="bibr">43</xref>]. Cytosine nucleosides (cytidine, deoxycytidine) are quite soluble in water (e.g., cytidine &#8805; 60 mg/mL in H<sub>2</sub>O) due to the presence of polar sugar groups, and their nucleotides are highly soluble (phosphate salts of nucleotides form compounds that hydrolyse in water) [<xref rid="B44-molecules-30-03598" ref-type="bibr">44</xref>]. As a result, cytosine metabolites circulating in the cell are readily soluble in the cytoplasm and easily transported.</p></sec><sec id="sec3dot4-molecules-30-03598"><title>3.4. Absorption Spectra and Other Properties</title><p>Cytosine and its pyrimidine derivatives show characteristic ultraviolet absorption spectra, with maxima associated with electron transitions in the conjugated ring system. For free cytosine in alkaline pH, the maximum absorption occurs at approx. 267 nm (&#949;&#8776;6.1 &#215; 10<sup>3</sup> M<sup>&#8722;1</sup>cm<sup>&#8722;1</sup>) and is stronger in the far UV range at ~197 nm. Cytosine nucleosides and nucleotides have similar spectra (e.g., for CMP, maximum at around 271 nm at neutral pH) [<xref rid="B45-molecules-30-03598" ref-type="bibr">45</xref>,<xref rid="B46-molecules-30-03598" ref-type="bibr">46</xref>]. These properties are used for practical purposes&#8212;measurement of absorbance at 260&#8211;270 nm is used for the detection and quantification of cytosine and its derivatives in chromatographic methods (HPLC with UV detection). In aqueous solutions, cytosine is relatively chemically stable under neutral conditions, but it degrades under the influence of UV light (photodegradation via photohydration and deamination reactions) and in extreme pH conditions. The high thermodynamic stability of the pyrimidine ring (aromaticity) of cytosine means that it does not easily open or break down. Only the action of specific enzymes or very strong reactants (e.g., peracetic acid) leads to the destruction of the ring.</p><sec><title>Properties and Applications of Selected Cytosine Derivatives</title><p><xref rid="molecules-30-03598-t001" ref-type="table">Table 1</xref> lists selected cytosine derivatives, both naturally occurring and of pharmacological interest, along with their selected physicochemical properties.</p><p>As shown in <xref rid="molecules-30-03598-t001" ref-type="table">Table 1</xref>, most derivatives of cytosine retain its essential characteristics, i.e., they are polar compounds, usually solids with high melting points (hydrogen bonds in the crystal lattice) and good solubility in water (especially their nucleoside/nucleotide forms), with similar UV spectra. The acid-base parameters remain similar to those of cytosine, with the exception of 5-halogenocytosines (significantly reduced pKa1) and triazine derivatives (5-azacytidine and analogues), where the introduction of an additional nitrogen atom in the ring increases the overall acidity of the compound. In chemical terms, these changes affect stability and reactions: for example, 5-azacytidine is less stable in solution (it is easily hydrolysed, its half-life in water is several hours at room temperature), which is related to the presence of an imino group in the position corresponding to C5. These properties are important for storage and administration of these compounds (5-aza-Cyd must be prepared immediately before use as a drug).</p><p>Cytosine is a compound with well-studied chemical properties, providing a reference point for many of its derivatives. Understanding these properties has led to the development of applications for many cytosine derivatives.</p></sec></sec></sec><sec id="sec4-molecules-30-03598"><title>4. Biological, Medical and Industrial Applications</title><sec id="sec4dot1-molecules-30-03598"><title>4.1. Biological Role of Cytosine and Its Derivatives</title><p>In biology, cytosine plays an indispensable role as an element of the genetic code in DNA and RNA. The sequences of bases in DNA, which also contain cytosine, carry genetic information in all organisms [<xref rid="B50-molecules-30-03598" ref-type="bibr">50</xref>,<xref rid="B51-molecules-30-03598" ref-type="bibr">51</xref>,<xref rid="B52-molecules-30-03598" ref-type="bibr">52</xref>,<xref rid="B53-molecules-30-03598" ref-type="bibr">53</xref>,<xref rid="B54-molecules-30-03598" ref-type="bibr">54</xref>,<xref rid="B55-molecules-30-03598" ref-type="bibr">55</xref>]. The complementary pairing of cytosine with guanine ensures the stability of the double helix and accurate copying of information during replication [<xref rid="B56-molecules-30-03598" ref-type="bibr">56</xref>]. Modifications of cytosine in DNA, primarily 5-methylcytosine (5mC), are a key element in the epigenetic regulation of gene activity [<xref rid="B57-molecules-30-03598" ref-type="bibr">57</xref>,<xref rid="B58-molecules-30-03598" ref-type="bibr">58</xref>,<xref rid="B59-molecules-30-03598" ref-type="bibr">59</xref>,<xref rid="B60-molecules-30-03598" ref-type="bibr">60</xref>]. In vertebrates, methylation of cytosine within CpG islands (regions in the genome with an increased content of 5&#8242;-CpG-3&#8242; dinucleotides relative to the genome average) in the promoters of genes typically silences their expression&#8212;this represents a mechanism of cell differentiation and genomic imprinting (one of the mechanisms of epigenetic modification of gene expression in the cell) [<xref rid="B61-molecules-30-03598" ref-type="bibr">61</xref>]. The presence of unmethylated CpG in therapeutic oligonucleotides is recognised by the immune system as a &#8216;foreign DNA signal&#8217;, leading to strong activation of the immune response. In contrast, replacing cytosine with its methylated form (5-mC) in CpG blocks recognition by TLR9, thereby preventing unwanted immune activation in therapeutic applications.</p><p>Methylation disorders (e.g., hypermethylation of tumour suppressors) lead to diseases, including cancer [<xref rid="B62-molecules-30-03598" ref-type="bibr">62</xref>,<xref rid="B63-molecules-30-03598" ref-type="bibr">63</xref>], so modulating 5mC levels has become a therapeutic target (e.g., azacitidine as a drug; <xref rid="molecules-30-03598-t001" ref-type="table">Table 1</xref>). Other natural derivatives, such as 5-hydroxymethylcytosine (5hmC), discovered in mammalian neurons, among others, probably act as mediators of active DNA demethylation and may themselves act as epigenetic signals [<xref rid="B64-molecules-30-03598" ref-type="bibr">64</xref>,<xref rid="B65-molecules-30-03598" ref-type="bibr">65</xref>,<xref rid="B66-molecules-30-03598" ref-type="bibr">66</xref>,<xref rid="B67-molecules-30-03598" ref-type="bibr">67</xref>,<xref rid="B68-molecules-30-03598" ref-type="bibr">68</xref>]. In bacterial DNA, N4-methylcytosine can be found, which is formed by the action of restriction methylases and protects the bacteria&#8217;s own DNA from degradation by the restriction&#8211;modification system (foreign DNA lacking this methylation is recognised and cut) [<xref rid="B69-molecules-30-03598" ref-type="bibr">69</xref>]. In RNA, on the other hand, cytosine is included in all major types of RNA (mRNA, tRNA, rRNA, snRNA). Its modifications in RNA (e.g., 5-methylcytosine in tRNA and rRNA) stabilise secondary and tertiary structures and affect translation efficiency [<xref rid="B70-molecules-30-03598" ref-type="bibr">70</xref>,<xref rid="B71-molecules-30-03598" ref-type="bibr">71</xref>].</p><p>In terms of metabolism, cytidine triphosphate (CTP) is not only a precursor of RNA, but also acts as a coenzyme&#8212;for example, CTP is a donor of phosphate residues in nucleoside phosphorylation reactions (CTP can transfer phosphate to ADP in the presence of specific kinases, converting it to ATP) [<xref rid="B72-molecules-30-03598" ref-type="bibr">72</xref>]. In addition, cytidine nucleotides are involved in the biosynthesis of cell membrane phospholipids, with CTP reacting with choline to form CDP-choline (cytidine diphosphocholine, known as citicoline), which is a key intermediate in the synthesis of phosphatidylcholine [<xref rid="B73-molecules-30-03598" ref-type="bibr">73</xref>,<xref rid="B74-molecules-30-03598" ref-type="bibr">74</xref>,<xref rid="B75-molecules-30-03598" ref-type="bibr">75</xref>]. Citicoline is sometimes used as a dietary supplement or agent in neurorehabilitation after stroke, providing the body with cytidine and choline to support the regeneration of neuronal membranes [<xref rid="B76-molecules-30-03598" ref-type="bibr">76</xref>].</p></sec><sec id="sec4dot2-molecules-30-03598"><title>4.2. Medical Applications as Cytosine Drugs</title><p>Minor structural changes in the cytosine molecule result in significant changes in physicochemical properties, ranging from tautomeric ability, solubility and chemical stability to affinity for metabolizing enzymes. These differences translate into varied biological activities of cytosine derivatives. Pure cytosine as a free base has no direct pharmacological activity, but it is a key biological element, as its methylation (5mC) in DNA is a fundamental epigenetic marker regulating gene activity [<xref rid="B77-molecules-30-03598" ref-type="bibr">77</xref>,<xref rid="B78-molecules-30-03598" ref-type="bibr">78</xref>]. Much more interesting is the biological activity of cytosine derivatives, many of which have found application as anticancer drugs, antiviral agents or antibiotics. Cytosine has been reflected in the development of many drugs that are analogues of cytosine or its nucleosides [<xref rid="B79-molecules-30-03598" ref-type="bibr">79</xref>,<xref rid="B80-molecules-30-03598" ref-type="bibr">80</xref>]. Due to the involvement of cytosine in critical processes (DNA replication, RNA transcription), its analogues most often act as antimetabolites, disrupting these processes in pathogens or cancer cells [<xref rid="B81-molecules-30-03598" ref-type="bibr">81</xref>,<xref rid="B82-molecules-30-03598" ref-type="bibr">82</xref>]. The most important examples include:<list list-type="bullet"><list-item><p>Anticancer drugs (antimetabolites): Cytarabine (Ara-C, cytosar) is 1-&#946;-D-arabinofuranosylcytosine, a cytidine analogue containing arabinose instead of ribose [<xref rid="B83-molecules-30-03598" ref-type="bibr">83</xref>,<xref rid="B84-molecules-30-03598" ref-type="bibr">84</xref>]. It was introduced for therapeutic use in the 1960s (approved by the FDA in 1969), it became the primary drug for treating acute leukaemia (especially acute myeloid leukaemia). When phosphorylated to ara-CTP, cytarabine is incorporated into DNA instead of deoxycytidine and causes inhibition of DNA chain elongation and polymerase function, leading to the death of rapidly dividing cancer cells [<xref rid="B85-molecules-30-03598" ref-type="bibr">85</xref>]. Gemcitabine (difluorodeoxycytidine, dFdC) is another cytostatic, a deoxycytidine analogue, in which the two hydrogen atoms at C2&#8242; of the sugar have been replaced by fluorine [<xref rid="B86-molecules-30-03598" ref-type="bibr">86</xref>,<xref rid="B87-molecules-30-03598" ref-type="bibr">87</xref>,<xref rid="B88-molecules-30-03598" ref-type="bibr">88</xref>]. Introduced in oncology in the 1990s (approved by the FDA in 1996 as a first-line drug for pancreatic cancer), gemcitabine has also been used in the treatment of non-small cell lung cancer, bladder cancer, breast cancer and other cancers [<xref rid="B89-molecules-30-03598" ref-type="bibr">89</xref>,<xref rid="B90-molecules-30-03598" ref-type="bibr">90</xref>,<xref rid="B91-molecules-30-03598" ref-type="bibr">91</xref>]. Its mechanism involves a dual action: in the form of triphosphate, it is incorporated into DNA, causing termination of synthesis, while gemcitabine diphosphate inhibits ribonucleotide reductase, reducing the pool of deoxyribonucleotides in the cell. Other important drugs are 5-azacytosine analogues: 5-Azacytidine (AZA, Vidaza<sup>&#174;</sup>) and 5-aza-2&#8242;-deoxycytidine (decitabine, Dacogen<sup>&#174;</sup>). These are nucleosides in which the C5 carbon atom of pyrimidine is replaced by nitrogen (the ring becomes a triazine). They incorporate into DNA (decitabine and azacitidine) or RNA (only azacitidine) and, due to the presence of nitrogen at position 5, are not subject to methylation by DNA methyltransferases [<xref rid="B92-molecules-30-03598" ref-type="bibr">92</xref>,<xref rid="B93-molecules-30-03598" ref-type="bibr">93</xref>]. Furthermore, they form covalent adducts with these enzymes, leading to their degradation. As a result, these drugs cause global DNA hypomethylation and re-activation of silenced suppressor genes in cancer cells. They were approved for the treatment of myelodysplastic syndromes (MDS) and certain types of leukaemia around 2004. Although they act atypically (not so much cytotoxically as epigenetically), they improve survival of MDS patients and are being intensively studied in combination with other therapies. Other cytidine analogues are also used in chemotherapy, such as <italic toggle="yes">azacitidine</italic> (liposomal DepoCyt<sup>&#174;</sup> for the treatment of CNS lymphomas) or <italic toggle="yes">gemcitabine</italic> (discussed above) [<xref rid="B94-molecules-30-03598" ref-type="bibr">94</xref>,<xref rid="B95-molecules-30-03598" ref-type="bibr">95</xref>]. New derivatives are also being developed, such as olutasydenib (FT-2102), a decitabine analogue with a modified structure, or RX-3117 (fluorocyclopentenylcytosine), a cytidine analogue active in some resistant cancers [<xref rid="B96-molecules-30-03598" ref-type="bibr">96</xref>].</p></list-item><list-item><p>Antiviral drugs: The structure of cytosine nucleosides provided the basis for the development of effective drugs against viruses, especially retroviruses and hepatitis B virus. <italic toggle="yes">Lamivudine</italic> (3TC) is a 2&#8242;,3&#8242;-dideoxy-3&#8242;-thiazolidinedione analogue of deoxycytidine, in which the ribose ring was replaced by a ring with a sulphur atom (thiazolidine), and the absence of 3&#8242;-OH groups prevents DNA chain elongation [<xref rid="B97-molecules-30-03598" ref-type="bibr">97</xref>]. Lamivudine was approved for the treatment of HIV-1 infections in 1995 and HBV in 1998, and has become a widely used component of antiretroviral therapy (it belongs to the NRTI class of nucleoside reverse transcriptase inhibitors) [<xref rid="B98-molecules-30-03598" ref-type="bibr">98</xref>,<xref rid="B99-molecules-30-03598" ref-type="bibr">99</xref>]. It acts as a terminator of viral DNA synthesis after incorporation by reverse transcriptase, while competitively inhibiting the enzyme itself. <italic toggle="yes">Emtricitabine</italic> (FTC), a fluorinated analogue of lamivudine (<xref rid="molecules-30-03598-f004" ref-type="fig">Figure 4</xref>), also used in the treatment of HIV&#8212;<italic toggle="yes">human immunodeficiency virus</italic> (often in composite formulations), has a similar effect.</p></list-item><list-item><p>Another example is <italic toggle="yes">cidofovir</italic>&#8212;although it is a nucleotide (phosphate) analogue of cytosine (<xref rid="molecules-30-03598-f005" ref-type="fig">Figure 5</xref>) rather than a nucleoside, it exhibits activity against many DNA viruses (CMV&#8212;<italic toggle="yes">Cytomegalovirus</italic>, adenoviruses, polio) by inhibiting viral DNA polymerase. It is used in CMV retinal infections [<xref rid="B100-molecules-30-03598" ref-type="bibr">100</xref>,<xref rid="B101-molecules-30-03598" ref-type="bibr">101</xref>].</p></list-item><list-item><p>In the context of new threats, the pro-drug <italic toggle="yes">molnupiravir</italic> (EIDD-2801) was emergency approved in 2021 for use against SARS-CoV-2 [<xref rid="B102-molecules-30-03598" ref-type="bibr">102</xref>,<xref rid="B103-molecules-30-03598" ref-type="bibr">103</xref>]. It is a modified ribonucleoside derivative of cytosine (N<sup>4</sup>-hydroxycytidine in the form of a pro-drug) which, when activated to triphosphate, incorporates into the virus RNA, causing lethal mutations in its genome. This is an example of the use of a cytosine derivative to induce viral replication errors. In the treatment of DNA viruses (such as HSV&#8212;<italic toggle="yes">herpes simplex virus</italic>), cytosine derivatives play a lesser role, and guanine analogues (acyclovir) are better known [<xref rid="B104-molecules-30-03598" ref-type="bibr">104</xref>,<xref rid="B105-molecules-30-03598" ref-type="bibr">105</xref>]. Nevertheless, work on cytidine analogues with activity against RNA and DNA viruses continues.</p></list-item><list-item><p>Antifungal drugs: The only commonly used antifungal antimetabolite is the aforementioned <italic toggle="yes">5-fluorocytosine</italic> (flucytosine, 5-FC) [<xref rid="B106-molecules-30-03598" ref-type="bibr">106</xref>,<xref rid="B107-molecules-30-03598" ref-type="bibr">107</xref>]. Introduced for the treatment of fungal infections in the 1970s, it is still used today (mainly in combination with amphotericin B) to treat cryptococcal meningitis and other severe fungemia [<xref rid="B108-molecules-30-03598" ref-type="bibr">108</xref>,<xref rid="B109-molecules-30-03598" ref-type="bibr">109</xref>]. 5-FC has no direct toxic effect on mammalian cells, as they are unable to metabolise it. In fungal cells, however, cytosine deaminase (enzyme) converts 5-FC to 5-fluorouracil (5-FU). 5-FU, in turn, is incorporated into RNA instead of uracil and inhibits thymidylate synthase (after conversion to 5-F-dUMP), which disrupts DNA synthesis. This results in a fungistatic (in higher doses fungicidal) effect of 5-FC. This drug is a valuable addition to therapy, although due to the rapid development of resistance (deaminase or pyrimidine permease mutations), it is mainly used in polytherapy. Flucytosine is an example of how a minor change in the molecule (a fluorine atom instead of hydrogen in the cytosine ring) adds a completely new pharmacological use to a compound.</p></list-item><list-item><p>Other pharmacological uses: In addition to the examples discussed above, it is worth mentioning that cytidine and its phosphates are present in dietary supplements and products designed to enhance brain function [<xref rid="B110-molecules-30-03598" ref-type="bibr">110</xref>]. The aforementioned citicoline (CDP-choline, which is cytidine diphosphate coupled with choline) is available as a preparation that improves cognitive function and accelerate neuronal regeneration after strokes. Its mechanism of action involves increasing the availability of cytidine (or rather uridine, which is produced from cytidine) and choline, precursors of the synthesis of important brain phospholipids. Another example is <italic toggle="yes">carmofur</italic>, a 5-FU derivative coupled with a carbamate residue, which also exhibits anticancer activity (although it is not a pure analogue of cytosine, but rather its metabolite) [<xref rid="B111-molecules-30-03598" ref-type="bibr">111</xref>]. An interesting fact is the use of cytosine analogues in biotechnology, e.g., for DNA labelling. The 5-bromocytosine can be incorporated in place of cytosine and then used for specific DNA cleavage with UV light (photochemically). In medical diagnostics, the 5mC methylation profile of a patient&#8217;s genome (the so-called methylome map) is analysed using chemical conversion of cytosine to uracil by the so-called bisulfide reaction. The reagent is sodium metabisulfite, which selectively deaminates cytosine to uracil, while 5-methylcytosine remains unaffected. This technique allows the methylation pattern to be read after DNA sequencing and is routinely used in epigenetics.</p></list-item></list></p><p>In summary, chemical modifications of cytosine lead to compounds with diverse biological activities. From nucleoside analogues that disrupt viral and cancer cell replication, through pro-drugs activated in microorganisms, to natural antibiotics, cytosine derivatives represent an important class of bioactive compounds in medicine and biology.</p></sec><sec id="sec4dot3-molecules-30-03598"><title>4.3. Industrial and Technological Applications</title><p>Apart from medicine and molecular biology, cytosine derivatives do not have very broad independent industrial applications. However, the production of nucleosides (including cytidine) and nucleotides has become important in the biotechnology and pharmaceutical industries. Cytidine is produced by fermentation or extraction (from yeast) as a raw material for the synthesis of the aforementioned citicoline or as a supplement. CTP and CDP-choline are used in nucleotide-enriched food preparations (e.g., some infant formulae contain nucleotide additives, including CMP, although adenosine and guanosine nucleotides are more commonly added as umami flavour enhancers) [<xref rid="B74-molecules-30-03598" ref-type="bibr">74</xref>,<xref rid="B75-molecules-30-03598" ref-type="bibr">75</xref>]. Cytosine derivatives interact with guanosine, most often maintaining the classic C&#8211;G hydrogen bond arrangement, but the nature of this interaction and its stability depend on the type of cytosine modification.</p><p>In biochemical laboratories, it is standard practice to use isotopically labelled derivatives of cytosine, such as tritiated cytidine (<sup>3</sup>H), to study metabolic pathways, DNA/RNA synthesis, etc. Synthetic derivatives are also produced on an industrial scale for scientific purposes, e.g., 5-ethynyl-2&#8242;-deoxycytidine (EdC), a nucleoside used for labelling newly synthesised DNA (so-called click chemistry in the detection of proliferating cells) [<xref rid="B112-molecules-30-03598" ref-type="bibr">112</xref>,<xref rid="B113-molecules-30-03598" ref-type="bibr">113</xref>]. In summary, the extra-cellular applications of cytosine are mainly in the specialised fields of biotechnology, diagnostics and pharmaceutical production, while its biological role is universal and crucial for life.</p></sec></sec><sec id="sec5-molecules-30-03598"><title>5. Analytics of Cytosine and Its Derivatives</title><p>The analysis of cytosine and its derivatives plays an important role both in basic research (e.g., determining the composition of bases in DNA, studying nucleotide metabolism) and in therapy monitoring (determining the concentration of drugs&#8212;cytosine analogues in the patient&#8217;s blood). Classical identification methods include colour reactions (e.g., Sakaguchi test modified for pyrimidines) and blotting or thin-layer chromatography (TLC) for separating mixtures of nitrogenous bases. Today, high-performance liquid chromatography (HPLC) and capillary electrophoresis techniques are standard, often combined with UV spectrophotometric detection or mass spectrometry (MS) methods. The HPLC technique is the most widespread in the analysis of nucleosides and their analogues.</p><sec id="sec5dot1-molecules-30-03598"><title>5.1. High-Performance Liquid Chromatography (HPLC)</title><p>The analysis of cytosine and its derivatives requires sensitive and selective methods capable of separating structurally very similar compounds. High-performance liquid chromatography is a widely used analytical technique for the determination of both free nitrogenous bases, nucleosides and their analogues in a variety of matrices (pure solutions, DNA hydrolysates, biological samples or pharmaceutical preparations) [<xref rid="B114-molecules-30-03598" ref-type="bibr">114</xref>,<xref rid="B115-molecules-30-03598" ref-type="bibr">115</xref>,<xref rid="B116-molecules-30-03598" ref-type="bibr">116</xref>,<xref rid="B117-molecules-30-03598" ref-type="bibr">117</xref>]. To achieve proper separation of structurally similar compounds, attention must be paid to key aspects of the HPLC methods used and the conditions of analysis:<list list-type="bullet"><list-item><p>Columns and stationary phases: The most commonly used are strongly hydrophobic C18-type (reversed-phase) columns with high inertness, allowing the separation of polar nucleosides in the water-organic solvent system [<xref rid="B118-molecules-30-03598" ref-type="bibr">118</xref>,<xref rid="B119-molecules-30-03598" ref-type="bibr">119</xref>]. However, separation of very similar cytosine analogues (e.g., 5 different epigenetic derivatives: C, 5mC, 5hmC, 5fC, 5caC) can sometimes be challenging. In such cases, modification of the stationary phase can improve selectivity. For example, using a phenyl-hexyl column instead of C18 increased the differences in cytosine vs. 5-hydroxymethylcytosine retention due to &#960;-&#960; interactions. This allowed for the separation of all five cytosine analogues associated with DNA demethylation, which was not achieved on the classical C18 column [<xref rid="B120-molecules-30-03598" ref-type="bibr">120</xref>]. In the analysis of highly polar derivatives, such as phosphate nucleotides, an ion-pairing reagent (e.g., tetrabutylammonium iodide) is often added to the mobile phase, or ion-exchange or HILIC (hydrophilic interaction chromatography) columns are used [<xref rid="B121-molecules-30-03598" ref-type="bibr">121</xref>]. These approaches increase the retention of ionic or highly polar compounds on the column.</p></list-item><list-item><p>Mobile phases: Buffered aqueous phases (e.g., ammonium or potassium phosphate buffer solutions with pH in the range of 4&#8211;7) combined with an organic solvent (methanol or acetonitrile) are typically used for the separation of cytosolic bases and nucleosides. The pH of the mobile phase is critical because it affects the degree of ionisation of analytes and interactions with the stationary phase [<xref rid="B120-molecules-30-03598" ref-type="bibr">120</xref>,<xref rid="B122-molecules-30-03598" ref-type="bibr">122</xref>]. Studies have shown that changes in pH induce the largest changes in the retention of cytosine and cytidine. A slightly acidic pH is usually maintained (approximately 4&#8211;6) to ensure that cytosine (pKa~4.5) is present in an ionised or partially ionised form, which reduces its retention and improves the shape of peaks. Elution gradients are often used in the analysis of mixtures of derivatives with significantly different polarities: for example, starting with a high proportion of water (or buffer) for the retention of polar nucleosides, and then gradually increasing the proportion of organic solvent to elute more non-polar analogues. This method was used to separate a mixture of cytosine and its modified derivatives, starting with 1% methanol in water with a buffer and reaching 30% methanol in several minutes, achieving excellent separation of all five analytes in &lt;12 min [<xref rid="B120-molecules-30-03598" ref-type="bibr">120</xref>].</p></list-item><list-item><p>Detectors and sensitivity: Cytosine derivatives have an aromatic system, so they strongly absorb UV light in the 260&#8211;280 nm range. The most common detection technique is therefore UV detection (often using a DAD, i.e., diode array detector), set, e.g., at 270&#8211;280 nm for cytosine nucleosides. UV detection usually allows for the detection of nanomolar amounts of analyte [<xref rid="B123-molecules-30-03598" ref-type="bibr">123</xref>,<xref rid="B124-molecules-30-03598" ref-type="bibr">124</xref>,<xref rid="B125-molecules-30-03598" ref-type="bibr">125</xref>]. For example, at a wavelength of 271 nm, the detection limit for cytidine in pharmaceutical analysis was about 0.15 ng and the limit of quantification was ~0.5 ng [<xref rid="B126-molecules-30-03598" ref-type="bibr">126</xref>]. The sensitivity of HPLC&#8211;UV can be improved by increasing the injection volume (up to several dozen &#956;L, if tolerated by the column) and by using sample extraction (analyte concentration) from the matrix. For applications requiring ultra-high sensitivity or selectivity (e.g., determination of trace modifications of bases in cellular DNA), mass spectrometry coupled with HPLC (LC-MS/MS) is used. The HPLC-ESI-MS/MS technique with selected reaction monitoring (MRM) enabled the simultaneous quantification of 5-methyl- and 5-hydroxy-2&#8242;-deoxycytidine alongside unaltered deoxycytidine with a detection limit of 0.5 femtomoles (corresponding to the analysis of 50 ng of hydrolysed genomic DNA, enabling the detection of 0.1% 5hmC content) [<xref rid="B127-molecules-30-03598" ref-type="bibr">127</xref>]. Such high sensitivity allows for precise profiling of global DNA methylation in biological samples.</p></list-item></list></p><p>In summary, cytosine, cytidine nucleosides and their derivatives are polar compounds that are difficult to separate on classical inverted columns (C18) without modifying the mobile phase. Under neutral conditions, these molecules are poorly separated on the non-polar phase (due to hydrophilicity), while under acidic conditions they become cations, which further reduces retention due to repulsion from the silanol groups remaining on the silica. Very good HPLC analysis results can be obtained by: (1) adding ion-pairing reactants to the mobile phase (e.g., alkyl sulfonates), which form ion pairs with cationic molecules that are more easily retained on the C18 column; (2) using an ion-exchange phase, such as a cation-exchange column for retaining pyrimidine cations; (3) using specialised columns for hydrophilic polar interaction chromatography or mixed columns with polar-ion groups.</p><p>A modern solution is the so-called BIST (Bridge Ion Separation Technology), which combines ionic and hydrophobic retention. An example is the method developed by SIELC Technologies for separating a mixture of cytosine, deoxycytidine and cytidine on a BIST B+ column. Under the conditions of this method (mobile phase: acetonitrile/water mixture with 0.2% H<sub>2</sub>SO<sub>4</sub>, column with quaternary amine groups on the surface), separation of three compounds was achieved in ~5 min, with retention times of approximately 2.8; 3.2 and 5.1 min, respectively. Sulphuric acid provides protonation of the analytes and the formation of &#8216;ion bridges&#8217; with the stationary phase, resulting in significant differences in retention despite similar structures [<xref rid="B128-molecules-30-03598" ref-type="bibr">128</xref>].</p><p>In a classical RP-HPLC system (C18 phase, UV detector), separation of pyrimidine nucleosides is also possible, but requires precise control of the pH and composition of the mobile phase. A study by Romanova and Novotny (1996) [<xref rid="B129-molecules-30-03598" ref-type="bibr">129</xref>] showed that the most important factor affecting cytosine and cytidine retention is the pH of the eluent. A change in pH from 5 to 7 caused a drastic increase in retention time due to the transition of cytosine from the cationic to the neutral form [<xref rid="B129-molecules-30-03598" ref-type="bibr">129</xref>]. In contrast, increasing the content of methanol in the mobile phase shortened retention times (as expected for revered-phase chromatography), while changes in temperature and flow had a lesser effect. With such optimisations, it is possible to separate mixtures of nucleosides by RP&#8211;HPLC in several minutes. For example, cytosine, uracil, cytidine, deoxycytidine and other metabolites can be separated in a single run of gradient HPLC with phosphate buffer and methanol [<xref rid="B130-molecules-30-03598" ref-type="bibr">130</xref>]. UV detection at 254&#8211;270 nm allows for picomole sensitivity for individual compounds. In addition, coupling HPLC with a mass detector (LC&#8211;MS) allows unambiguous identification of analysed derivatives on the basis of their mass spectra [<xref rid="B131-molecules-30-03598" ref-type="bibr">131</xref>,<xref rid="B132-molecules-30-03598" ref-type="bibr">132</xref>]. In the case of cytostatic analogues (e.g., cytarabine, gemcitabine), LC&#8211;MS/MS is routinely used to monitor pharmacokinetics, as these compounds are detected in plasma at nanomole concentrations due to specific fragmentations in the spectrometer. For example, gemcitabine (mass 264u) contains a characteristic fragment (mass 112, after sugar loss), which allows for sensitive quantitative determination in patients receiving therapy [<xref rid="B133-molecules-30-03598" ref-type="bibr">133</xref>].</p><p>The authors of this article also studied the separation of isomers of cytosine derivatives. The study involved the separation of cytokine derivative isomers in the form of three isomeric bromine derivatives [<xref rid="B134-molecules-30-03598" ref-type="bibr">134</xref>], which are N1-substituted benzylcytosines (differing in the position of the bromine in the benzyl ring; <xref rid="molecules-30-03598-f006" ref-type="fig">Figure 6</xref>).</p><p>Attempts at separation on standard C18 and C8 phases were unsuccessful as the isomers eluted together regardless of the composition of the mobile phase. Only the use of a column with a chemically attached naphthylpropyl ligand (aromatic phase) enabled the effective separation of these isomers in less than 7 min [<xref rid="B135-molecules-30-03598" ref-type="bibr">135</xref>]. The aromatic phase promotes isomer differentiation through specific &#960;-&#960; interactions and selective geometric matching [<xref rid="B136-molecules-30-03598" ref-type="bibr">136</xref>,<xref rid="B137-molecules-30-03598" ref-type="bibr">137</xref>]. The authors achieved high separation selectivity (coefficients &#945; = 1.90 and 1.53 between consecutive isomers; <xref rid="molecules-30-03598-f007" ref-type="fig">Figure 7</xref>). The aforementioned chemically bonded naphthylpropyl stationary phase was successfully used to separate a wide variety of derivatives with similar structures containing an aromatic ring [<xref rid="B138-molecules-30-03598" ref-type="bibr">138</xref>,<xref rid="B139-molecules-30-03598" ref-type="bibr">139</xref>,<xref rid="B140-molecules-30-03598" ref-type="bibr">140</xref>].</p><p>In summary, the above examples show that even structurally very similar derivatives can be separated chromatographically with proper optimisation, which is important, for example, in drug quality control, where individual isomers or synthesis by-products must be detected and determined. The HPLC technique is an indispensable tool in the analysis of cytosine and its derivatives. It allows the separation of even structurally very similar analogues by selecting the appropriate column and elution conditions, and in combination with sensitive detectors (UV-DAD, MS/MS) enables the detection of trace amounts of these compounds in complex matrices. HPLC techniques are used in quality control of drug substances (e.g., purity and stability of cytosine analogues in pharmaceutical preparations), in monitoring the pharmacokinetics of anticancer and antiviral drugs (determination of plasma concentrations), as well as in basic research [<xref rid="B141-molecules-30-03598" ref-type="bibr">141</xref>]. With the continuous development of chromatography, such as the use of ultra-high performance liquid chromatography (UHPLC) and improvements in MS detection, the scope and precision of analyses of cytosine and its derivatives continues to expand, supporting advances in chemistry, biology and medicine.</p></sec><sec id="sec5dot2-molecules-30-03598"><title>5.2. Chromatography and Electrophoresis for DNA/RNA Studies</title><p>In laboratory analysis of DNA base composition, separation of the products of total nucleic acid hydrolysis is commonly used. DNA hydrolysed by acid (or enzymatically by nucleases to a mixture of nucleosides) can be analysed by reversed-phase HPLC. Individual deoxyribonucleosides (dA, dG, dC, dT) elute in a specific order and are detected spectrophotometrically. This allows, for example, the determination of the overall level of methylation (by comparing the ratio of dC to 5mdC). In research practice, tandem MS is used to determine modified bases (such as 5hmC, 5fC, 5caC) due to their very low amounts in DNA. It is worth noting that commercial HPLC columns specifically designed for nucleotide separation are available. They often use ion exchange mechanisms, e.g., with amine groups. An alternative method is high-performance capillary electrophoresis (HPCE)&#8212;a high-resolution technique where nucleosides are separated based on differences in charge and size in an electric field [<xref rid="B142-molecules-30-03598" ref-type="bibr">142</xref>]. It has been successfully used to analyse mixtures of nitrogenous bases and nucleosides, although it requires UV detection in the far ultraviolet (which is sometimes less sensitive).</p></sec><sec id="sec5dot3-molecules-30-03598"><title>5.3. Other Analytical Methods</title><p>In addition to HPLC, spectroscopic methods are also used in the analysis of cytosine and its derivatives. UV-VIS spectroscopy is used for rapid determination of the total content (e.g., measurement of absorbance at 260 nm gives the total content of a mixture of nucleic bases, used for determining DNA/RNA concentration) [<xref rid="B143-molecules-30-03598" ref-type="bibr">143</xref>,<xref rid="B144-molecules-30-03598" ref-type="bibr">144</xref>]. Fluorescence spectroscopy has limited application because cytosine and nucleosides are not naturally fluorescent. However, it is possible to determine them indirectly after labelling with dyes, e.g., using Hantzsch&#8217;s reagent, which forms a fluorescent derivative of ureides, a technique used in early methods of RNA determination. A highly sensitive method is GC-MS after prior derivatisation of bases into volatile derivatives, e.g., cytosine forms trimethylsilyl derivatives, which can be separated by gas chromatography and detected by mass spectrometry. This technique has been used to study prebiotic experiments (searching for cytosine in abiotic mixtures). Finally, the aforementioned enzymatic methods are popular in molecular biology. For example, cytosine deaminase can be used for the differential determination of 5mC vs. C (5mC is not a substrate for the enzyme). Overall, however, high-performance liquid chromatography with various modifications remains the &#8216;gold standard&#8217; for the analysis of cytosine and derivatives, from simple base separation to complex mixtures of pharmaceutical analogues. Its advantage is that it combines UV detection (universal for aromatic compounds) and MS (for selectivity) to provide reliable identification and quantitative precision necessary in science and diagnostics [<xref rid="B145-molecules-30-03598" ref-type="bibr">145</xref>].</p></sec></sec><sec sec-type="conclusions" id="sec6-molecules-30-03598"><title>6. Conclusions</title><p>Cytosine is not only an elementary component of nucleic acids, but also a chemical platform for many compounds of great biological and medical importance. Its chemical properties, i.e., an aromatic pyrimidine ring capable of tautomerism, moderate basicity and modifiability, determine both the stability of genetic information and the possibility of subtle epigenetic regulation through methylation. Cytosine derivatives play key roles in gene regulation (5-mC, 5-hmC), and their synthetically produced analogues have become powerful tools for treating diseases (antimetabolites&#8212;cytarabine, gemcitabine, azacitidine; antiretroviral drugs&#8212;lamivudine, etc.). Understanding the metabolism of cytosine (biosynthesis from UTP, degradation to &#946;-alanine) has provided a foundation of biochemical knowledge, while the development of analytical methods has made it possible to track its fate in the cell and the therapeutic effects of its analogues. Modern analytics, especially HPLC techniques, enable the effective separation and determination of cytosine and its derivatives, even in complex biological matrices, which is essential, for example, in epigenomics (5-mC determination) or drug pharmacokinetics. Various research works show that methods for separating even very similar structures of cytosine derivatives are constantly being improved, which is important for the development of new drugs and quality control. In summary, cytosine is a crucial nexus between chemistry and biology&#8212;from the very beginnings of life (the problem of cytosine abiogenesis), through genetic and epigenetic mechanisms, to the design of life-saving drugs. Its numerous derivatives, both natural and synthetic, expand the range of functions and applications of this seemingly &#8220;ordinary&#8221; nucleotide base. Thanks to intensive research on cytosine, we now have both a profound understanding of biological processes and specific tools for modelling them in medicine and biotechnology.</p></sec></body><back><fn-group><fn><p><bold>Disclaimer/Publisher&#8217;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><notes><title>Author Contributions</title><p>Conceptualization, M.K.; methodology, M.K. and J.J.; formal analysis, M.K. and J.J.; investigation, M.K.; D.P. and W.P.; resources, M.K.; D.P. and W.P. writing&#8212;original draft preparation, M.K. and J.J.; writing&#8212;review and editing, M.K. and J.J.; supervision, M.K.; funding acquisition, M.K. and J.J. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Institutional Review Board Statement</title><p>Not applicable.</p></notes><notes><title>Informed Consent Statement</title><p>Not applicable.</p></notes><notes notes-type="data-availability"><title>Data Availability Statement</title><p>No new data were created or analyzed in this study. Data sharing is not applicable to this article.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest.</p></notes><ref-list><title>References</title><ref id="B1-molecules-30-03598"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Obara</surname><given-names>P.</given-names></name><name name-style="western"><surname>Wolski</surname><given-names>P.</given-names></name><name name-style="western"><surname>Pa&#324;czyk</surname><given-names>T.</given-names></name></person-group><article-title>Insights into the Molecular Structure, Stability, and Biological Significance of Non-Canonical DNA Forms, with a Focus on G-Quadruplexes and i-Motifs</article-title><source>Molecules</source><year>2024</year><volume>29</volume><elocation-id>4683</elocation-id><pub-id pub-id-type="doi">10.3390/molecules29194683</pub-id><pub-id pub-id-type="pmid">39407611</pub-id><pub-id pub-id-type="pmcid">PMC11477922</pub-id></element-citation></ref><ref id="B2-molecules-30-03598"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>F.</given-names></name><name name-style="western"><surname>Li</surname><given-names>P.</given-names></name><name name-style="western"><surname>Chu</surname><given-names>H.C.</given-names></name><name name-style="western"><surname>Lo</surname><given-names>P.K.</given-names></name></person-group><article-title>Nucleic Acids and Their Analogues for Biomedical Applications</article-title><source>Biosensors</source><year>2022</year><volume>12</volume><elocation-id>93</elocation-id><pub-id pub-id-type="doi">10.3390/bios12020093</pub-id><pub-id pub-id-type="pmid">35200353</pub-id><pub-id pub-id-type="pmcid">PMC8869748</pub-id></element-citation></ref><ref id="B3-molecules-30-03598"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kossel</surname><given-names>A.</given-names></name><name name-style="western"><surname>Neumann</surname><given-names>A.</given-names></name></person-group><article-title>&#220;ber das Cytosin, eine neue Base aus dem Thymusnuklein</article-title><source>Z. Physiol. Chem.</source><year>1894</year><volume>18</volume><fpage>181</fpage><lpage>186</lpage></element-citation></ref><ref id="B4-molecules-30-03598"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>El-Atawy</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Alshaye</surname><given-names>N.A.</given-names></name><name name-style="western"><surname>Elrubi</surname><given-names>N.</given-names></name><name name-style="western"><surname>Hamed</surname><given-names>E.A.</given-names></name><name name-style="western"><surname>Omar</surname><given-names>A.Z.</given-names></name></person-group><article-title>Pyrimidines-Based Heterocyclic Compounds: Synthesis, Cytoxicity Evaluation and Molecular Docking</article-title><source>Molecules</source><year>2022</year><volume>27</volume><elocation-id>4912</elocation-id><pub-id pub-id-type="doi">10.3390/molecules27154912</pub-id><pub-id pub-id-type="pmid">35956864</pub-id><pub-id pub-id-type="pmcid">PMC9370056</pub-id></element-citation></ref><ref id="B5-molecules-30-03598"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mohi El-Deen</surname><given-names>E.M.</given-names></name><name name-style="western"><surname>Anwar</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>El-Gwaad</surname><given-names>A.A.A.</given-names></name><name name-style="western"><surname>Karam</surname><given-names>E.A.</given-names></name><name name-style="western"><surname>El-Ashrey</surname><given-names>M.K.</given-names></name><name name-style="western"><surname>Kassab</surname><given-names>R.R.</given-names></name></person-group><article-title>Novel Pyridothienopyrimidine Derivatives: Design, Synthesis and Biological Evaluation as Antimicrobial and Anticancer Agents</article-title><source>Molecules</source><year>2022</year><volume>27</volume><elocation-id>803</elocation-id><pub-id pub-id-type="doi">10.3390/molecules27030803</pub-id><pub-id pub-id-type="pmid">35164067</pub-id><pub-id pub-id-type="pmcid">PMC8839448</pub-id></element-citation></ref><ref id="B6-molecules-30-03598"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Se&#269;nik</surname><given-names>A.</given-names></name><name name-style="western"><surname>&#352;tajner</surname><given-names>N.</given-names></name><name name-style="western"><surname>Radi&#353;ek</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kunej</surname><given-names>U.</given-names></name><name name-style="western"><surname>Kri&#382;man</surname><given-names>M.</given-names></name><name name-style="western"><surname>Jak&#353;e</surname><given-names>J.</given-names></name></person-group><article-title>Cytosine Methylation in Genomic DNA and Characterization of DNA Methylases and Demethylases and Their Expression Profiles in Viroid-Infected Hop Plants (<italic toggle="yes">Humulus lupulus</italic> Var. &#8216;Celeia&#8217;)</article-title><source>Cells</source><year>2022</year><volume>11</volume><elocation-id>2592</elocation-id><pub-id pub-id-type="doi">10.3390/cells11162592</pub-id><pub-id pub-id-type="pmid">36010668</pub-id><pub-id pub-id-type="pmcid">PMC9406385</pub-id></element-citation></ref><ref id="B7-molecules-30-03598"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alom</surname><given-names>K.M.</given-names></name><name name-style="western"><surname>Tukova</surname><given-names>A.</given-names></name><name name-style="western"><surname>Lyu</surname><given-names>N.</given-names></name><name name-style="western"><surname>Rodger</surname><given-names>A.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name></person-group><article-title>Label-Free Surface-Enhanced Raman Scattering for Genomic DNA Cytosine Methylation Reading</article-title><source>Molecules</source><year>2025</year><volume>30</volume><elocation-id>403</elocation-id><pub-id pub-id-type="doi">10.3390/molecules30020403</pub-id><pub-id pub-id-type="pmid">39860272</pub-id><pub-id pub-id-type="pmcid">PMC11767753</pub-id></element-citation></ref><ref id="B8-molecules-30-03598"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Andr&#233;s</surname><given-names>C.M.C.</given-names></name><name name-style="western"><surname>Lastra</surname><given-names>J.M.P.D.L.</given-names></name><name name-style="western"><surname>Juan</surname><given-names>C.A.</given-names></name><name name-style="western"><surname>Plou</surname><given-names>F.J.</given-names></name><name name-style="western"><surname>P&#233;rez-Lebe&#241;a</surname><given-names>E.</given-names></name></person-group><article-title>Chemical Insights into Oxidative and Nitrative Modifications of DNA</article-title><source>Int. J. Mol. Sci.</source><year>2023</year><volume>24</volume><elocation-id>15240</elocation-id><pub-id pub-id-type="doi">10.3390/ijms242015240</pub-id><pub-id pub-id-type="pmid">37894920</pub-id><pub-id pub-id-type="pmcid">PMC10607741</pub-id></element-citation></ref><ref id="B9-molecules-30-03598"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>B&#233;k&#233;si</surname><given-names>A.</given-names></name><name name-style="western"><surname>Holub</surname><given-names>E.</given-names></name><name name-style="western"><surname>P&#225;link&#225;s</surname><given-names>H.L.</given-names></name><name name-style="western"><surname>V&#233;rtessy</surname><given-names>B.G.</given-names></name></person-group><article-title>Detection of Genomic Uracil Patterns</article-title><source>Int. J. Mol. Sci.</source><year>2021</year><volume>22</volume><elocation-id>3902</elocation-id><pub-id pub-id-type="doi">10.3390/ijms22083902</pub-id><pub-id pub-id-type="pmid">33918885</pub-id><pub-id pub-id-type="pmcid">PMC8070346</pub-id></element-citation></ref><ref id="B10-molecules-30-03598"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Du</surname><given-names>L.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>R.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Z.</given-names></name></person-group><article-title>5-Methylcytosine Methylation-Linked Hippo Pathway Molecular Interactions Regulate Lipid Metabolism</article-title><source>Int. J. Mol. Sci.</source><year>2025</year><volume>26</volume><elocation-id>2560</elocation-id><pub-id pub-id-type="doi">10.3390/ijms26062560</pub-id><pub-id pub-id-type="pmid">40141201</pub-id><pub-id pub-id-type="pmcid">PMC11942534</pub-id></element-citation></ref><ref id="B11-molecules-30-03598"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hanson</surname><given-names>H.E.</given-names></name><name name-style="western"><surname>Liebl</surname><given-names>A.L.</given-names></name></person-group><article-title>The Mutagenic Consequences of DNA Methylation within and across Generations</article-title><source>Epigenomes</source><year>2022</year><volume>6</volume><elocation-id>33</elocation-id><pub-id pub-id-type="doi">10.3390/epigenomes6040033</pub-id><pub-id pub-id-type="pmid">36278679</pub-id><pub-id pub-id-type="pmcid">PMC9624357</pub-id></element-citation></ref><ref id="B12-molecules-30-03598"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nikulina</surname><given-names>A.N.</given-names></name><name name-style="western"><surname>Nikulin</surname><given-names>N.A.</given-names></name><name name-style="western"><surname>Suzina</surname><given-names>N.E.</given-names></name><name name-style="western"><surname>Zimin</surname><given-names>A.A.</given-names></name></person-group><article-title>Treatment of <italic toggle="yes">E. coli</italic> Infections with T4-Related Bacteriophages Belonging to Class <italic toggle="yes">Caudoviricetes</italic>: Selecting Phage on the Basis of Their Generalized Transduction Capability</article-title><source>Viruses</source><year>2025</year><volume>17</volume><elocation-id>701</elocation-id><pub-id pub-id-type="doi">10.3390/v17050701</pub-id><pub-id pub-id-type="pmid">40431712</pub-id><pub-id pub-id-type="pmcid">PMC12115623</pub-id></element-citation></ref><ref id="B13-molecules-30-03598"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Urbonavi&#269;ius</surname><given-names>J.</given-names></name><name name-style="western"><surname>&#268;ekyt&#279;</surname><given-names>A.</given-names></name><name name-style="western"><surname>Taurait&#279;</surname><given-names>D.</given-names></name></person-group><article-title>N<sup>4</sup>-Methylcytosine Supports the Growth of <italic toggle="yes">Escherichia coli</italic> Uracil Auxotrophs</article-title><source>Int. J. Mol. Sci.</source><year>2025</year><volume>26</volume><elocation-id>1812</elocation-id><pub-id pub-id-type="doi">10.3390/ijms26051812</pub-id><pub-id pub-id-type="pmid">40076440</pub-id><pub-id pub-id-type="pmcid">PMC11898903</pub-id></element-citation></ref><ref id="B14-molecules-30-03598"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Halder</surname><given-names>R.K.</given-names></name><name name-style="western"><surname>Uddin</surname><given-names>M.N.</given-names></name><name name-style="western"><surname>Uddin</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Aryal</surname><given-names>S.</given-names></name><name name-style="western"><surname>Islam</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Hossain</surname><given-names>F.</given-names></name><name name-style="western"><surname>Jahan</surname><given-names>N.</given-names></name><name name-style="western"><surname>Khraisat</surname><given-names>A.</given-names></name><name name-style="western"><surname>Alazab</surname><given-names>A.</given-names></name></person-group><article-title>A Grid Search-Based Multilayer Dynamic Ensemble System to Identify DNA N4&#8212;Methylcytosine Using Deep Learning Approach</article-title><source>Genes</source><year>2023</year><volume>14</volume><elocation-id>582</elocation-id><pub-id pub-id-type="doi">10.3390/genes14030582</pub-id><pub-id pub-id-type="pmid">36980853</pub-id><pub-id pub-id-type="pmcid">PMC10048346</pub-id></element-citation></ref><ref id="B15-molecules-30-03598"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bernaola-Galv&#225;n</surname><given-names>P.</given-names></name><name name-style="western"><surname>Carpena</surname><given-names>P.</given-names></name><name name-style="western"><surname>G&#243;mez-Mart&#237;n</surname><given-names>C.</given-names></name><name name-style="western"><surname>Oliver</surname><given-names>J.L.</given-names></name></person-group><article-title>Compositional Structure of the Genome: A Review</article-title><source>Biology</source><year>2023</year><volume>12</volume><elocation-id>849</elocation-id><pub-id pub-id-type="doi">10.3390/biology12060849</pub-id><pub-id pub-id-type="pmid">37372134</pub-id><pub-id pub-id-type="pmcid">PMC10295253</pub-id></element-citation></ref><ref id="B16-molecules-30-03598"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Foerstner</surname><given-names>K.U.</given-names></name><name name-style="western"><surname>Mering</surname><given-names>C.</given-names></name><name name-style="western"><surname>Hooper</surname><given-names>S.D.</given-names></name><name name-style="western"><surname>Bork</surname><given-names>P.</given-names></name></person-group><article-title>Environments shape the nucleotide composition of genomes</article-title><source>Sci. Rep.</source><year>2005</year><volume>6</volume><fpage>1208</fpage><lpage>1213</lpage><pub-id pub-id-type="doi">10.1038/sj.embor.7400538</pub-id><pub-id pub-id-type="pmid">16200051</pub-id><pub-id pub-id-type="pmcid">PMC1369203</pub-id></element-citation></ref><ref id="B17-molecules-30-03598"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Piovesan</surname><given-names>A.</given-names></name><name name-style="western"><surname>Pelleri</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>Antonaros</surname><given-names>F.</given-names></name><name name-style="western"><surname>Strippoli</surname><given-names>P.</given-names></name><name name-style="western"><surname>Caracausi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Vitale</surname><given-names>L.</given-names></name></person-group><article-title>On the length, weight and GC content of the human genome</article-title><source>BMC Res. Notes</source><year>2019</year><volume>12</volume><elocation-id>106</elocation-id><pub-id pub-id-type="doi">10.1186/s13104-019-4137-z</pub-id><pub-id pub-id-type="pmid">30813969</pub-id><pub-id pub-id-type="pmcid">PMC6391780</pub-id></element-citation></ref><ref id="B18-molecules-30-03598"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Song</surname><given-names>H.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>B.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Cai</surname><given-names>B.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Straube</surname><given-names>J.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>T.</given-names></name></person-group><article-title>Biological roles of RNA m<sup>5</sup>C modification and its implications in Cancer immunotherapy</article-title><source>Biomark. Res.</source><year>2022</year><volume>10</volume><elocation-id>15</elocation-id><pub-id pub-id-type="doi">10.1186/s40364-022-00362-8</pub-id><pub-id pub-id-type="pmid">35365216</pub-id><pub-id pub-id-type="pmcid">PMC8973801</pub-id></element-citation></ref><ref id="B19-molecules-30-03598"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bhakta</surname><given-names>S.</given-names></name><name name-style="western"><surname>Tsukahara</surname><given-names>T.</given-names></name></person-group><article-title>C-to-U RNA Editing: A Site Directed RNA Editing Tool for Restoration of Genetic Code</article-title><source>Genes</source><year>2022</year><volume>13</volume><elocation-id>1636</elocation-id><pub-id pub-id-type="doi">10.3390/genes13091636</pub-id><pub-id pub-id-type="pmid">36140804</pub-id><pub-id pub-id-type="pmcid">PMC9498875</pub-id></element-citation></ref><ref id="B20-molecules-30-03598"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>G.</given-names></name><name name-style="western"><surname>Li</surname><given-names>D.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>T.</given-names></name><name name-style="western"><surname>He</surname><given-names>S.</given-names></name></person-group><article-title>Pyrimidine Biosynthetic Enzyme CAD: Its Function, Regulation, and Diagnostic Potential</article-title><source>Int. J. Mol. Sci.</source><year>2021</year><volume>22</volume><elocation-id>10253</elocation-id><pub-id pub-id-type="doi">10.3390/ijms221910253</pub-id><pub-id pub-id-type="pmid">34638594</pub-id><pub-id pub-id-type="pmcid">PMC8508918</pub-id></element-citation></ref><ref id="B21-molecules-30-03598"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gorgoglione</surname><given-names>R.</given-names></name><name name-style="western"><surname>Impedovo</surname><given-names>V.</given-names></name><name name-style="western"><surname>Riley</surname><given-names>C.L.</given-names></name><name name-style="western"><surname>Fratantonio</surname><given-names>D.</given-names></name><name name-style="western"><surname>Tiziani</surname><given-names>S.</given-names></name><name name-style="western"><surname>Palmieri</surname><given-names>L.</given-names></name><name name-style="western"><surname>Dolce</surname><given-names>V.</given-names></name><name name-style="western"><surname>Fiermonte</surname><given-names>G.</given-names></name></person-group><article-title>Glutamine-Derived Aspartate Biosynthesis in Cancer Cells: Role of Mitochondrial Transporters and New Therapeutic Perspectives</article-title><source>Cancers</source><year>2022</year><volume>14</volume><elocation-id>245</elocation-id><pub-id pub-id-type="doi">10.3390/cancers14010245</pub-id><pub-id pub-id-type="pmid">35008407</pub-id><pub-id pub-id-type="pmcid">PMC8750728</pub-id></element-citation></ref><ref id="B22-molecules-30-03598"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bayram</surname><given-names>S.</given-names></name><name name-style="western"><surname>F&#252;rst</surname><given-names>S.</given-names></name><name name-style="western"><surname>Forbes</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kempa</surname><given-names>S.</given-names></name></person-group><article-title>Analysing central metabolism in ultra-high resolution: At the crossroads of carbon and nitrogen</article-title><source>Mol. Metab.</source><year>2019</year><volume>33</volume><fpage>38</fpage><lpage>47</lpage><pub-id pub-id-type="doi">10.1016/j.molmet.2019.12.002</pub-id><pub-id pub-id-type="pmid">31928927</pub-id><pub-id pub-id-type="pmcid">PMC7056925</pub-id></element-citation></ref><ref id="B23-molecules-30-03598"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yadav</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kumar</surname><given-names>R.</given-names></name><name name-style="western"><surname>Krishnamurthy</surname><given-names>R.</given-names></name></person-group><article-title>Chemistry of Abiotic Nucleotide Synthesis</article-title><source>Chem. Rev.</source><year>2020</year><volume>120</volume><fpage>4766</fpage><lpage>4805</lpage><pub-id pub-id-type="doi">10.1021/acs.chemrev.9b00546</pub-id><pub-id pub-id-type="pmid">31916751</pub-id></element-citation></ref><ref id="B24-molecules-30-03598"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kornienko</surname><given-names>I.V.</given-names></name><name name-style="western"><surname>Aramova</surname><given-names>O.Y.</given-names></name><name name-style="western"><surname>Tishchenko</surname><given-names>A.A.</given-names></name><name name-style="western"><surname>Rudoy</surname><given-names>D.V.</given-names></name><name name-style="western"><surname>Chikindas</surname><given-names>M.L.</given-names></name></person-group><article-title>RNA Stability: A Review of the Role of Structural Features and Environmental Conditions</article-title><source>Molecules</source><year>2024</year><volume>29</volume><elocation-id>5978</elocation-id><pub-id pub-id-type="doi">10.3390/molecules29245978</pub-id><pub-id pub-id-type="pmid">39770066</pub-id><pub-id pub-id-type="pmcid">PMC11676819</pub-id></element-citation></ref><ref id="B25-molecules-30-03598"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nicu</surname><given-names>A.-T.</given-names></name><name name-style="western"><surname>Ionel</surname><given-names>I.P.</given-names></name><name name-style="western"><surname>Stoica</surname><given-names>I.</given-names></name><name name-style="western"><surname>Burlibasa</surname><given-names>L.</given-names></name><name name-style="western"><surname>Jinga</surname><given-names>V.</given-names></name></person-group><article-title>Recent Advancements in Research on DNA Methylation and Testicular Germ Cell Tumors: Unveiling the Intricate Relationship</article-title><source>Biomedicines</source><year>2024</year><volume>12</volume><elocation-id>1041</elocation-id><pub-id pub-id-type="doi">10.3390/biomedicines12051041</pub-id><pub-id pub-id-type="pmid">38791003</pub-id><pub-id pub-id-type="pmcid">PMC11117643</pub-id></element-citation></ref><ref id="B26-molecules-30-03598"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Podolyan</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Gorb</surname><given-names>L.</given-names></name><name name-style="western"><surname>Leszczynski</surname><given-names>J.</given-names></name></person-group><article-title>Ab Initio Study of the Prototropic Tautomerism of Cytosine and Guanine and Their Contribution to Spontaneous Point Mutations</article-title><source>Int. J. Mol. Sci.</source><year>2003</year><volume>4</volume><fpage>410</fpage><lpage>421</lpage><pub-id pub-id-type="doi">10.3390/i4070410</pub-id></element-citation></ref><ref id="B27-molecules-30-03598"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stoyanova</surname><given-names>N.</given-names></name><name name-style="western"><surname>Enchev</surname><given-names>V.</given-names></name></person-group><article-title>Tautomerism of cytosine, cytidine, and deoxycytidine: Proton transfer through water bridges</article-title><source>Int. J. Quantum Chem.</source><year>2022</year><volume>18</volume><fpage>e26958</fpage><pub-id pub-id-type="doi">10.1002/qua.26958</pub-id></element-citation></ref><ref id="B28-molecules-30-03598"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bazs&#243;</surname><given-names>G.</given-names></name><name name-style="western"><surname>Tarczay</surname><given-names>G.</given-names></name><name name-style="western"><surname>Fogarasi</surname><given-names>G.</given-names></name><name name-style="western"><surname>Szalay</surname><given-names>P.</given-names></name></person-group><article-title>Tautomers of cytosine and their excited electronic states: A matrix isolation spectroscopic and quantum chemical study</article-title><source>Phys. Chem. Chem. Phys.</source><year>2011</year><volume>13</volume><fpage>6799</fpage><lpage>6807</lpage><pub-id pub-id-type="doi">10.1039/c0cp02354j</pub-id><pub-id pub-id-type="pmid">21234503</pub-id></element-citation></ref><ref id="B29-molecules-30-03598"><label>29.</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Mizerski</surname><given-names>W.</given-names></name></person-group><source>Tablice Chemiczne</source><edition>7th ed.</edition><publisher-name>Adamantan</publisher-name><publisher-loc>Warszawa, Poland</publisher-loc><year>2025</year><fpage>307</fpage><lpage>308</lpage><comment>(In Polish)</comment></element-citation></ref><ref id="B30-molecules-30-03598"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Raczy&#324;ska</surname><given-names>E.D.</given-names></name></person-group><article-title>On Prototropy and Bond Length Alternation in Neutral and Ionized Pyrimidine Bases and Their Model Azines in Vacuo</article-title><source>Molecules</source><year>2023</year><volume>28</volume><elocation-id>7282</elocation-id><pub-id pub-id-type="doi">10.3390/molecules28217282</pub-id><pub-id pub-id-type="pmid">37959699</pub-id><pub-id pub-id-type="pmcid">PMC10648772</pub-id></element-citation></ref><ref id="B31-molecules-30-03598"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Constantinescu</surname><given-names>T.</given-names></name><name name-style="western"><surname>Lungu</surname><given-names>C.N.</given-names></name></person-group><article-title>Anticancer Activity of Natural and Synthetic Chalcones</article-title><source>Int. J. Mol. Sci.</source><year>2021</year><volume>22</volume><elocation-id>11306</elocation-id><pub-id pub-id-type="doi">10.3390/ijms222111306</pub-id><pub-id pub-id-type="pmid">34768736</pub-id><pub-id pub-id-type="pmcid">PMC8582663</pub-id></element-citation></ref><ref id="B32-molecules-30-03598"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Coates</surname><given-names>E.</given-names></name><name name-style="western"><surname>Marsden</surname><given-names>C.G.</given-names></name><name name-style="western"><surname>Rigg</surname><given-names>B.</given-names></name></person-group><article-title>Ionization of cysteine in aqueous solutions. Part 2.&#8212;Specific-ionization constants</article-title><source>Trans. Faraday Soc.</source><year>1969</year><volume>65</volume><fpage>3032</fpage><pub-id pub-id-type="doi">10.1039/tf9696503032</pub-id></element-citation></ref><ref id="B33-molecules-30-03598"><label>33.</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Saenger</surname><given-names>W.</given-names></name></person-group><article-title>Physical Properties of Nucleotides: Charge Densities, p<italic toggle="yes">K</italic> Values, Spectra, and Tautomerism</article-title><source>Principles of Nucleic Acid Structure</source><comment>Springer Advanced Texts in Chemistry</comment><publisher-name>Springer</publisher-name><publisher-loc>New York, NY, USA</publisher-loc><year>1984</year><fpage>105</fpage><lpage>115</lpage><pub-id pub-id-type="doi">10.1007/978-1-4612-5190-3_5</pub-id></element-citation></ref><ref id="B34-molecules-30-03598"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Durant</surname><given-names>C.</given-names></name><name name-style="western"><surname>Strege</surname><given-names>M.</given-names></name></person-group><article-title>A Hydrophilic Interaction Chromatography Method for the Purity Analysis of Cytosine</article-title><source>LCGC N. Am.</source><year>2008</year><volume>26</volume><fpage>632</fpage><lpage>642</lpage></element-citation></ref><ref id="B35-molecules-30-03598"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mohajeri</surname><given-names>A.</given-names></name><name name-style="western"><surname>Nobandegani</surname><given-names>F.F.</given-names></name></person-group><article-title>Detection and evaluation of hydrogen bond strength in nucleic acid base pairs</article-title><source>J. Phys. Chem. A</source><year>2008</year><volume>112</volume><fpage>281</fpage><lpage>295</lpage><pub-id pub-id-type="doi">10.1021/jp075992a</pub-id><pub-id pub-id-type="pmid">18085756</pub-id></element-citation></ref><ref id="B36-molecules-30-03598"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Aschi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Toto Brocchi</surname><given-names>G.</given-names></name><name name-style="western"><surname>Portalone</surname><given-names>G.</given-names></name></person-group><article-title>A Combined Experimental and Computational Study of Halogen and Hydrogen Bonding in Molecular Salts of 5-Bromocytosine</article-title><source>Molecules</source><year>2021</year><volume>26</volume><elocation-id>3111</elocation-id><pub-id pub-id-type="doi">10.3390/molecules26113111</pub-id><pub-id pub-id-type="pmid">34070959</pub-id><pub-id pub-id-type="pmcid">PMC8196974</pub-id></element-citation></ref><ref id="B37-molecules-30-03598"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Martel</surname><given-names>P.</given-names></name><name name-style="western"><surname>Powell</surname><given-names>B.M.</given-names></name></person-group><article-title>Dehydration of cytosine monohydrate at physiological temperatures</article-title><source>Biophys. J.</source><year>1983</year><volume>41</volume><fpage>91</fpage><lpage>93</lpage><pub-id pub-id-type="doi">10.1016/S0006-3495(83)84409-9</pub-id><pub-id pub-id-type="pmid">6824757</pub-id><pub-id pub-id-type="pmcid">PMC1329017</pub-id></element-citation></ref><ref id="B38-molecules-30-03598"><label>38.</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Mastropietro</surname><given-names>T.F.</given-names></name><name name-style="western"><surname>De Munno</surname><given-names>G.</given-names></name></person-group><article-title>Cytosine and Its Derivatives as Useful Tools to Build Unusual and Fascinating Architectures</article-title><source>Modern Avenues in Metal-Nucleic Acid Chemistry</source><edition>1st ed.</edition><person-group person-group-type="editor"><name name-style="western"><surname>M&#252;ller</surname><given-names>B.</given-names></name><name name-style="western"><surname>Lipper</surname><given-names>B.</given-names></name></person-group><publisher-name>CRC Press</publisher-name><publisher-loc>Boca Raton, FL, USA</publisher-loc><year>2023</year><pub-id pub-id-type="doi">10.1201/9781003270201</pub-id></element-citation></ref><ref id="B39-molecules-30-03598"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yousif</surname><given-names>H.N.</given-names></name><name name-style="western"><surname>Jabbar</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Al-zahawi</surname><given-names>H.M.G.</given-names></name></person-group><article-title>Synthesis and identification of new cytosine-derived compounds and study their binding with DNA</article-title><source>Mater. Today Proc.</source><year>2022</year><volume>49</volume><fpage>2666</fpage><lpage>2670</lpage><pub-id pub-id-type="doi">10.1016/j.matpr.2021.08.336</pub-id></element-citation></ref><ref id="B40-molecules-30-03598"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rausch</surname><given-names>C.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>P.</given-names></name><name name-style="western"><surname>Casas-Delucchi</surname><given-names>C.S.</given-names></name><name name-style="western"><surname>Dai&#223;</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Engel</surname><given-names>C.</given-names></name><name name-style="western"><surname>Coster</surname><given-names>G.</given-names></name><name name-style="western"><surname>Hastert</surname><given-names>F.D.</given-names></name><name name-style="western"><surname>Weber</surname><given-names>P.</given-names></name><name name-style="western"><surname>Cardoso</surname><given-names>M.C.</given-names></name></person-group><article-title>Cytosine base modifications regulate DNA duplex stability and metabolism</article-title><source>Nucleic Acids Res.</source><year>2021</year><volume>49</volume><fpage>12870</fpage><lpage>12894</lpage><pub-id pub-id-type="doi">10.1093/nar/gkab509</pub-id><pub-id pub-id-type="pmid">34133727</pub-id><pub-id pub-id-type="pmcid">PMC8682791</pub-id></element-citation></ref><ref id="B41-molecules-30-03598"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Islam</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Ibnat</surname><given-names>Z.</given-names></name></person-group><article-title>New Insights into the Structure and Reactivity of Uracil Derivatives in Different Solvents&#8212;A Computational Study</article-title><source>ACS Omega</source><year>2020</year><volume>5</volume><fpage>22449</fpage><lpage>22458</lpage><pub-id pub-id-type="doi">10.1021/acsomega.0c02943</pub-id><pub-id pub-id-type="pmid">32923803</pub-id><pub-id pub-id-type="pmcid">PMC7482307</pub-id></element-citation></ref><ref id="B42-molecules-30-03598"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Braun</surname><given-names>D.E.</given-names></name><name name-style="western"><surname>Kahlenberg</surname><given-names>V.</given-names></name><name name-style="western"><surname>Griesser</surname><given-names>U.J.</given-names></name></person-group><article-title>Experimental and Computational Hydrate Screening: Cytosine, 5-Flucytosine and Their Solid Solution</article-title><source>Cryst. Growth Des.</source><year>2017</year><volume>17</volume><fpage>4347</fpage><lpage>4364</lpage><pub-id pub-id-type="doi">10.1021/acs.cgd.7b00664</pub-id><pub-id pub-id-type="pmcid">PMC6193535</pub-id><pub-id pub-id-type="pmid">30344452</pub-id></element-citation></ref><ref id="B43-molecules-30-03598"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sigera</surname><given-names>L.S.</given-names></name><name name-style="western"><surname>Denning</surname><given-names>D.W.</given-names></name></person-group><article-title>Flucytosine and its clinical usage</article-title><source>Ther. Adv. Infect. Dis.</source><year>2023</year><volume>10</volume><pub-id pub-id-type="doi">10.1177/20499361231161387</pub-id><pub-id pub-id-type="pmcid">PMC10084540</pub-id><pub-id pub-id-type="pmid">37051439</pub-id></element-citation></ref><ref id="B44-molecules-30-03598"><label>44.</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Lewis</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Larra&#241;aga</surname><given-names>M.D.</given-names></name><name name-style="western"><surname>Lewis</surname><given-names>R.J.</given-names></name></person-group><source>Hawley&#8217;s Condensed Chemical Dictionary</source><edition>16th ed.</edition><publisher-name>John Wiley &amp; Sons</publisher-name><publisher-loc>Hoboken, NJ, USA</publisher-loc><year>2016</year><fpage>688</fpage></element-citation></ref><ref id="B45-molecules-30-03598"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Elangovan</surname><given-names>N.</given-names></name><name name-style="western"><surname>Arumugam</surname><given-names>N.</given-names></name><name name-style="western"><surname>Almansour</surname><given-names>A.I.</given-names></name><name name-style="western"><surname>Djearamane</surname><given-names>S.</given-names></name><name name-style="western"><surname>Wong</surname><given-names>L.S.</given-names></name><name name-style="western"><surname>Kayarohanam</surname><given-names>S.</given-names></name></person-group><article-title>Synthesis, solvent role, absorption and emission studies of cytosine derivative</article-title><source>Heliyon</source><year>2024</year><volume>10</volume><fpage>e28623</fpage><pub-id pub-id-type="doi">10.1016/j.heliyon.2024.e28623</pub-id><pub-id pub-id-type="pmid">38590870</pub-id><pub-id pub-id-type="pmcid">PMC11000011</pub-id></element-citation></ref><ref id="B46-molecules-30-03598"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stimson</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Reuter</surname><given-names>M.A.</given-names></name></person-group><article-title>The ultraviolet absorption spectra of cytosine and isocytosine</article-title><source>J. Am. Chem. Soc.</source><year>1945</year><volume>67</volume><fpage>2191</fpage><lpage>2193</lpage><pub-id pub-id-type="doi">10.1021/ja01228a040</pub-id><pub-id pub-id-type="pmid">21005686</pub-id></element-citation></ref><ref id="B47-molecules-30-03598"><label>47.</label><element-citation publication-type="webpage"><article-title>ChemicalBook</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.chemicalbook.com/" ext-link-type="uri">https://www.chemicalbook.com/</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2025-06-29">(accessed on 29 June 2025)</date-in-citation></element-citation></ref><ref id="B48-molecules-30-03598"><label>48.</label><element-citation publication-type="gov"><person-group person-group-type="author"><collab>National Institute of Standards and Technology</collab></person-group><article-title>NIST&#8212;Advancing Measurement Science, Standards, and Technology</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.nist.gov/" ext-link-type="uri">https://www.nist.gov/</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2025-06-29">(accessed on 29 June 2025)</date-in-citation></element-citation></ref><ref id="B49-molecules-30-03598"><label>49.</label><element-citation publication-type="gov"><person-group person-group-type="author"><collab>National Center for Biotechnology Information</collab></person-group><article-title>PubChem Compound Summary</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://pubchem.ncbi.nlm.nih.gov/" ext-link-type="uri">https://pubchem.ncbi.nlm.nih.gov/</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2025-06-29">(accessed on 29 June 2025)</date-in-citation></element-citation></ref><ref id="B50-molecules-30-03598"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Delma</surname><given-names>F.Z.</given-names></name><name name-style="western"><surname>Al-Hatmi</surname><given-names>A.M.S.</given-names></name><name name-style="western"><surname>Br&#252;ggemann</surname><given-names>R.J.M.</given-names></name><name name-style="western"><surname>Melchers</surname><given-names>W.J.G.</given-names></name><name name-style="western"><surname>de Hoog</surname><given-names>S.</given-names></name><name name-style="western"><surname>Verweij</surname><given-names>P.E.</given-names></name><name name-style="western"><surname>Buil</surname><given-names>J.B.</given-names></name></person-group><article-title>Molecular Mechanisms of 5-Fluorocytosine Resistance in Yeasts and Filamentous Fungi</article-title><source>J. Fungi</source><year>2021</year><volume>7</volume><elocation-id>909</elocation-id><pub-id pub-id-type="doi">10.3390/jof7110909</pub-id><pub-id pub-id-type="pmcid">PMC8623157</pub-id><pub-id pub-id-type="pmid">34829198</pub-id></element-citation></ref><ref id="B51-molecules-30-03598"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bruch</surname><given-names>A.</given-names></name><name name-style="western"><surname>Lazarova</surname><given-names>V.</given-names></name><name name-style="western"><surname>Berg</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kr&#252;ger</surname><given-names>T.</given-names></name><name name-style="western"><surname>Sch&#228;uble</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kelani</surname><given-names>A.A.</given-names></name><name name-style="western"><surname>Mertens</surname><given-names>B.</given-names></name><name name-style="western"><surname>Lehenberger</surname><given-names>P.</given-names></name><name name-style="western"><surname>Kniemeyer</surname><given-names>O.</given-names></name><name name-style="western"><surname>Kaiser</surname><given-names>S.</given-names></name><etal/></person-group><article-title>tRNA hypomodification facilitates 5-fluorocytosine resistance via cross-pathway control system activation in <italic toggle="yes">Aspergillus fumigatus</italic></article-title><source>Nucleic Acids Res.</source><year>2025</year><volume>53</volume><fpage>gkae1205</fpage><pub-id pub-id-type="doi">10.1093/nar/gkae1205</pub-id><pub-id pub-id-type="pmid">39711467</pub-id><pub-id pub-id-type="pmcid">PMC11797069</pub-id></element-citation></ref><ref id="B52-molecules-30-03598"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Galmarini</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Mackey</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>Dumontet</surname><given-names>C.</given-names></name></person-group><article-title>Nucleoside analogues: Mechanisms of drug resistance and reversal strategies</article-title><source>Leukemia</source><year>2001</year><volume>15</volume><fpage>875</fpage><lpage>890</lpage><pub-id pub-id-type="doi">10.1038/sj.leu.2402114</pub-id><pub-id pub-id-type="pmid">11417472</pub-id></element-citation></ref><ref id="B53-molecules-30-03598"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tsesmetzis</surname><given-names>N.</given-names></name><name name-style="western"><surname>Paulin</surname><given-names>C.B.J.</given-names></name><name name-style="western"><surname>Rudd</surname><given-names>S.G.</given-names></name><name name-style="western"><surname>Herold</surname><given-names>N.</given-names></name></person-group><article-title>Nucleobase and Nucleoside Analogues: Resistance and Re-Sensitisation at the Level of Pharmacokinetics, Pharmacodynamics and Metabolism</article-title><source>Cancers</source><year>2018</year><volume>10</volume><elocation-id>240</elocation-id><pub-id pub-id-type="doi">10.3390/cancers10070240</pub-id><pub-id pub-id-type="pmid">30041457</pub-id><pub-id pub-id-type="pmcid">PMC6071274</pub-id></element-citation></ref><ref id="B54-molecules-30-03598"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Batasheva</surname><given-names>S.</given-names></name><name name-style="western"><surname>Fakhrullin</surname><given-names>R.</given-names></name></person-group><article-title>Sequence Does Not Matter: The Biomedical Applications of DNA-Based Coatings and Cores</article-title><source>Int. J. Mol. Sci.</source><year>2021</year><volume>22</volume><elocation-id>12884</elocation-id><pub-id pub-id-type="doi">10.3390/ijms222312884</pub-id><pub-id pub-id-type="pmid">34884687</pub-id><pub-id pub-id-type="pmcid">PMC8658021</pub-id></element-citation></ref><ref id="B55-molecules-30-03598"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alanazi</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Muhiuddin</surname><given-names>G.</given-names></name><name name-style="western"><surname>Al-Balawi</surname><given-names>D.A.</given-names></name><name name-style="western"><surname>Samanta</surname><given-names>S.</given-names></name></person-group><article-title>Different DNA Sequencing Using DNA Graphs: A Study</article-title><source>Appl. Sci.</source><year>2022</year><volume>12</volume><elocation-id>5414</elocation-id><pub-id pub-id-type="doi">10.3390/app12115414</pub-id></element-citation></ref><ref id="B56-molecules-30-03598"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nie</surname><given-names>P.</given-names></name><name name-style="western"><surname>Bai</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Mei</surname><given-names>H.</given-names></name></person-group><article-title>Synthetic Life with Alternative Nucleic Acids as Genetic Materials</article-title><source>Molecules</source><year>2020</year><volume>25</volume><elocation-id>3483</elocation-id><pub-id pub-id-type="doi">10.3390/molecules25153483</pub-id><pub-id pub-id-type="pmid">32751873</pub-id><pub-id pub-id-type="pmcid">PMC7435384</pub-id></element-citation></ref><ref id="B57-molecules-30-03598"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hajnic</surname><given-names>M.</given-names></name><name name-style="western"><surname>Alonso-Gil</surname><given-names>S.</given-names></name><name name-style="western"><surname>Polyansky</surname><given-names>A.A.</given-names></name><name name-style="western"><surname>de Ruiter</surname><given-names>A.</given-names></name><name name-style="western"><surname>Zagrovic</surname><given-names>B.</given-names></name></person-group><article-title>Interaction preferences between protein side chains and key epigenetic modifications 5-methylcytosine, 5-hydroxymethycytosine and N<sup>6</sup>-methyladenine</article-title><source>Sci. Rep.</source><year>2022</year><volume>12</volume><elocation-id>19583</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-022-23585-z</pub-id><pub-id pub-id-type="pmid">36380112</pub-id><pub-id pub-id-type="pmcid">PMC9666514</pub-id></element-citation></ref><ref id="B58-molecules-30-03598"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lv</surname><given-names>S.</given-names></name><name name-style="western"><surname>Pan</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>T.</given-names></name><name name-style="western"><surname>Cao</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>B.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>F.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>D.</given-names></name></person-group><article-title>The Role of Methylation Modification in Neural Injury and Repair</article-title><source>Int. J. Mol. Sci.</source><year>2025</year><volume>26</volume><elocation-id>5349</elocation-id><pub-id pub-id-type="doi">10.3390/ijms26115349</pub-id><pub-id pub-id-type="pmid">40508158</pub-id><pub-id pub-id-type="pmcid">PMC12155110</pub-id></element-citation></ref><ref id="B59-molecules-30-03598"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cadet</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wagner</surname><given-names>J.R.</given-names></name></person-group><article-title>TET enzymatic oxidation of 5-methylcytosine, 5-hydroxymethylcytosine and 5-formylcytosine</article-title><source>Mutat. Res.</source><year>2016</year><volume>764&#8211;765</volume><fpage>18</fpage><lpage>35</lpage><pub-id pub-id-type="doi">10.1016/j.mrgentox.2013.09.001</pub-id><pub-id pub-id-type="pmid">24045206</pub-id></element-citation></ref><ref id="B60-molecules-30-03598"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Bao</surname><given-names>D.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>H.</given-names></name><name name-style="western"><surname>Gong</surname><given-names>M.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>S.</given-names></name><name name-style="western"><surname>Zou</surname><given-names>G.</given-names></name></person-group><article-title>Cross-Kingdom DNA Methylation Dynamics: Comparative Mechanisms of 5mC/6mA Regulation and Their Implications in Epigenetic Disorders</article-title><source>Biology</source><year>2025</year><volume>14</volume><elocation-id>461</elocation-id><pub-id pub-id-type="doi">10.3390/biology14050461</pub-id><pub-id pub-id-type="pmid">40427651</pub-id><pub-id pub-id-type="pmcid">PMC12108942</pub-id></element-citation></ref><ref id="B61-molecules-30-03598"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nishiki</surname><given-names>H.</given-names></name><name name-style="western"><surname>Ura</surname><given-names>H.</given-names></name><name name-style="western"><surname>Togi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Hatanaka</surname><given-names>H.</given-names></name><name name-style="western"><surname>Fujita</surname><given-names>H.</given-names></name><name name-style="western"><surname>Takamura</surname><given-names>H.</given-names></name><name name-style="western"><surname>Niida</surname><given-names>Y.</given-names></name></person-group><article-title>Integrated Analysis of Somatic DNA Variants and DNA Methylation of Tumor Suppressor Genes in Colorectal Cancer</article-title><source>Int. J. Mol. Sci.</source><year>2025</year><volume>26</volume><elocation-id>1642</elocation-id><pub-id pub-id-type="doi">10.3390/ijms26041642</pub-id><pub-id pub-id-type="pmid">40004106</pub-id><pub-id pub-id-type="pmcid">PMC11855003</pub-id></element-citation></ref><ref id="B62-molecules-30-03598"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vaidya</surname><given-names>H.</given-names></name><name name-style="western"><surname>Jelinek</surname><given-names>J.</given-names></name><name name-style="western"><surname>Issa</surname><given-names>J.-P.J.</given-names></name></person-group><article-title>DNA Methylation, Aging, and Cancer</article-title><source>Epigenomes</source><year>2025</year><volume>9</volume><elocation-id>18</elocation-id><pub-id pub-id-type="doi">10.3390/epigenomes9020018</pub-id><pub-id pub-id-type="pmid">40558829</pub-id><pub-id pub-id-type="pmcid">PMC12192155</pub-id></element-citation></ref><ref id="B63-molecules-30-03598"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ng</surname><given-names>J.M.-K.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>J.</given-names></name></person-group><article-title>Promoter Hypermethylation of Tumour Suppressor Genes as Potential Biomarkers in Colorectal Cancer</article-title><source>Int. J. Mol. Sci.</source><year>2015</year><volume>16</volume><fpage>2472</fpage><lpage>2496</lpage><pub-id pub-id-type="doi">10.3390/ijms16022472</pub-id><pub-id pub-id-type="pmid">25622259</pub-id><pub-id pub-id-type="pmcid">PMC4346847</pub-id></element-citation></ref><ref id="B64-molecules-30-03598"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Meng</surname><given-names>H.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>G.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>H.-M.</given-names></name><name name-style="western"><surname>Song</surname><given-names>X.</given-names></name><name name-style="western"><surname>Shi</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Cao</surname><given-names>L.</given-names></name></person-group><article-title>The Emerging Nexus of Active DNA Demethylation and Mitochondrial Oxidative Metabolism in Post-Mitotic Neurons</article-title><source>Int. J. Mol. Sci.</source><year>2014</year><volume>15</volume><fpage>22604</fpage><lpage>22625</lpage><pub-id pub-id-type="doi">10.3390/ijms151222604</pub-id><pub-id pub-id-type="pmid">25490140</pub-id><pub-id pub-id-type="pmcid">PMC4284726</pub-id></element-citation></ref><ref id="B65-molecules-30-03598"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zheng</surname><given-names>K.</given-names></name><name name-style="western"><surname>Lyu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>J.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>G.</given-names></name></person-group><article-title>5-Hydroxymethylcytosine: Far Beyond the Intermediate of DNA Demethylation</article-title><source>Int. J. Mol. Sci.</source><year>2024</year><volume>25</volume><elocation-id>11780</elocation-id><pub-id pub-id-type="doi">10.3390/ijms252111780</pub-id><pub-id pub-id-type="pmid">39519332</pub-id><pub-id pub-id-type="pmcid">PMC11546248</pub-id></element-citation></ref><ref id="B66-molecules-30-03598"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Klungland</surname><given-names>A.</given-names></name><name name-style="western"><surname>Robertson</surname><given-names>A.B.</given-names></name></person-group><article-title>Oxidized C5-methyl cytosine bases in DNA: 5-Hydroxymethylcytosine; 5-formylcytosine; and 5-carboxycytosine</article-title><source>Free Radic. Biol. Med.</source><year>2017</year><volume>107</volume><fpage>62</fpage><lpage>68</lpage><pub-id pub-id-type="doi">10.1016/j.freeradbiomed.2016.11.038</pub-id><pub-id pub-id-type="pmid">27890639</pub-id></element-citation></ref><ref id="B67-molecules-30-03598"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stoyanova</surname><given-names>E.</given-names></name><name name-style="western"><surname>Riad</surname><given-names>M.</given-names></name><name name-style="western"><surname>Rao</surname><given-names>A.</given-names></name><name name-style="western"><surname>Heintz</surname><given-names>N.</given-names></name></person-group><article-title>5-Hydroxymethylcytosine-mediated active demethylation is required for mammalian neuronal differentiation and function</article-title><source>Elife</source><year>2021</year><volume>10</volume><fpage>e66973</fpage><pub-id pub-id-type="doi">10.7554/eLife.66973</pub-id><pub-id pub-id-type="pmid">34919053</pub-id><pub-id pub-id-type="pmcid">PMC8683082</pub-id></element-citation></ref><ref id="B68-molecules-30-03598"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Besaratinia</surname><given-names>A.</given-names></name><name name-style="western"><surname>Caceres</surname><given-names>A.</given-names></name><name name-style="western"><surname>Tommasi</surname><given-names>S.</given-names></name></person-group><article-title>DNA Hydroxymethylation in Smoking-Associated Cancers</article-title><source>Int. J. Mol. Sci.</source><year>2022</year><volume>23</volume><elocation-id>2657</elocation-id><pub-id pub-id-type="doi">10.3390/ijms23052657</pub-id><pub-id pub-id-type="pmid">35269796</pub-id><pub-id pub-id-type="pmcid">PMC8910185</pub-id></element-citation></ref><ref id="B69-molecules-30-03598"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alam</surname><given-names>W.</given-names></name><name name-style="western"><surname>Tayara</surname><given-names>H.</given-names></name><name name-style="western"><surname>Chong</surname><given-names>K.T.</given-names></name></person-group><article-title>i4mC-Deep: An Intelligent Predictor of N4-Methylcytosine Sites Using a Deep Learning Approach with Chemical Properties</article-title><source>Genes</source><year>2021</year><volume>12</volume><elocation-id>1117</elocation-id><pub-id pub-id-type="doi">10.3390/genes12081117</pub-id><pub-id pub-id-type="pmid">34440291</pub-id><pub-id pub-id-type="pmcid">PMC8393747</pub-id></element-citation></ref><ref id="B70-molecules-30-03598"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>V&#228;re</surname><given-names>V.Y.P.</given-names></name><name name-style="western"><surname>Eruysal</surname><given-names>E.R.</given-names></name><name name-style="western"><surname>Narendran</surname><given-names>A.</given-names></name><name name-style="western"><surname>Sarachan</surname><given-names>K.L.</given-names></name><name name-style="western"><surname>Agris</surname><given-names>P.F.</given-names></name></person-group><article-title>Chemical and Conformational Diversity of Modified Nucleosides Affects tRNA Structure and Function</article-title><source>Biomolecules</source><year>2017</year><volume>7</volume><elocation-id>29</elocation-id><pub-id pub-id-type="doi">10.3390/biom7010029</pub-id><pub-id pub-id-type="pmid">28300792</pub-id><pub-id pub-id-type="pmcid">PMC5372741</pub-id></element-citation></ref><ref id="B71-molecules-30-03598"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Fang</surname><given-names>J.</given-names></name></person-group><article-title>RNA 5-methylcytosine modification and its emerging role as an epitranscriptomic mark</article-title><source>RNA Biol.</source><year>2021</year><volume>18</volume><fpage>117</fpage><lpage>127</lpage><pub-id pub-id-type="doi">10.1080/15476286.2021.1950993</pub-id><pub-id pub-id-type="pmid">34288807</pub-id><pub-id pub-id-type="pmcid">PMC8677007</pub-id></element-citation></ref><ref id="B72-molecules-30-03598"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>V&#225;vra</surname><given-names>J.</given-names></name><name name-style="western"><surname>Sergunin</surname><given-names>A.</given-names></name><name name-style="western"><surname>Farn&#225;</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ovad</surname><given-names>T.</given-names></name><name name-style="western"><surname>Shimizu</surname><given-names>T.</given-names></name><name name-style="western"><surname>Mart&#237;nkov&#225;</surname><given-names>M.</given-names></name></person-group><article-title>Is ATP the Only Nucleoside Triphosphate among ATP, CTP, GTP, and UTP to Have a Role in Kinase Catalysis of Heme-Regulated Inhibitor toward eIF2&#945; during Lung Cancer Development?</article-title><source>Catalysts</source><year>2023</year><volume>13</volume><elocation-id>281</elocation-id><pub-id pub-id-type="doi">10.3390/catal13020281</pub-id></element-citation></ref><ref id="B73-molecules-30-03598"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ren</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Cai</surname><given-names>M.</given-names></name></person-group><article-title>Engineering substrate and energy metabolism for living cell production of cytidine-5&#8242;-diphosphocholine</article-title><source>Biotechnol. Bioeng.</source><year>2020</year><volume>117</volume><fpage>1426</fpage><lpage>1435</lpage><pub-id pub-id-type="doi">10.1002/bit.27291</pub-id><pub-id pub-id-type="pmid">31997310</pub-id></element-citation></ref><ref id="B74-molecules-30-03598"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Adibhatla</surname><given-names>R.M.</given-names></name><name name-style="western"><surname>Hatcher</surname><given-names>J.F.</given-names></name><name name-style="western"><surname>Dempsey</surname><given-names>R.J.</given-names></name></person-group><article-title>Cytidine-5-diphosphocholine (CDP-choline) affects CTP: Phosphocholine cytidylyltransferase and lyso-phosphatidylcholine after transient brain ischemia</article-title><source>J. Neurosci. Res.</source><year>2004</year><volume>76</volume><fpage>390</fpage><lpage>396</lpage><pub-id pub-id-type="doi">10.1002/jnr.20078</pub-id><pub-id pub-id-type="pmid">15079868</pub-id></element-citation></ref><ref id="B75-molecules-30-03598"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fagone</surname><given-names>P.</given-names></name><name name-style="western"><surname>Jackowski</surname><given-names>S.</given-names></name></person-group><article-title>Phosphatidylcholine and the CDP-Choline Cycle</article-title><source>Biochim. Biophys. Acta Mol. Cell. Biol. Lipids</source><year>2012</year><volume>1832</volume><fpage>523</fpage><lpage>532</lpage><pub-id pub-id-type="doi">10.1016/j.bbalip.2012.09.009</pub-id><pub-id pub-id-type="pmcid">PMC3562404</pub-id><pub-id pub-id-type="pmid">23010477</pub-id></element-citation></ref><ref id="B76-molecules-30-03598"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Secades</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Trimmel</surname><given-names>H.</given-names></name><name name-style="western"><surname>Salazar</surname><given-names>B.</given-names></name><name name-style="western"><surname>Gonz&#225;lez</surname><given-names>J.A.</given-names></name></person-group><article-title>Citicoline for the Management of Patients with Traumatic Brain Injury in the Acute Phase: A Systematic Review and Meta-Analysis</article-title><source>Life</source><year>2023</year><volume>13</volume><elocation-id>369</elocation-id><pub-id pub-id-type="doi">10.3390/life13020369</pub-id><pub-id pub-id-type="pmid">36836726</pub-id><pub-id pub-id-type="pmcid">PMC9958735</pub-id></element-citation></ref><ref id="B77-molecules-30-03598"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Moore</surname><given-names>L.D.</given-names></name><name name-style="western"><surname>Le</surname><given-names>T.</given-names></name><name name-style="western"><surname>Fan</surname><given-names>G.</given-names></name></person-group><article-title>DNA Methylation and Its Basic Function</article-title><source>Neuropsychopharmacology</source><year>2012</year><volume>38</volume><fpage>23</fpage><lpage>38</lpage><pub-id pub-id-type="doi">10.1038/npp.2012.112</pub-id><pub-id pub-id-type="pmid">22781841</pub-id><pub-id pub-id-type="pmcid">PMC3521964</pub-id></element-citation></ref><ref id="B78-molecules-30-03598"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hangan</surname><given-names>A.C.</given-names></name><name name-style="western"><surname>Oprean</surname><given-names>L.S.</given-names></name><name name-style="western"><surname>Dican</surname><given-names>L.</given-names></name><name name-style="western"><surname>Procopciuc</surname><given-names>L.M.</given-names></name><name name-style="western"><surname>Sevastre</surname><given-names>B.</given-names></name><name name-style="western"><surname>Lucaciu</surname><given-names>R.L.</given-names></name></person-group><article-title>Metal-Based Drug&#8211;DNA Interactions and Analytical Determination Methods</article-title><source>Molecules</source><year>2024</year><volume>29</volume><elocation-id>4361</elocation-id><pub-id pub-id-type="doi">10.3390/molecules29184361</pub-id><pub-id pub-id-type="pmid">39339356</pub-id><pub-id pub-id-type="pmcid">PMC11434005</pub-id></element-citation></ref><ref id="B79-molecules-30-03598"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kawsar</surname><given-names>S.M.A.</given-names></name><name name-style="western"><surname>Tabassum</surname><given-names>R.</given-names></name><name name-style="western"><surname>Munia</surname><given-names>N.S.</given-names></name><name name-style="western"><surname>Mali</surname><given-names>S.N.</given-names></name><name name-style="western"><surname>Lai</surname><given-names>C.</given-names></name><name name-style="western"><surname>Ferdous</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ali</surname><given-names>F.</given-names></name></person-group><article-title>Potential antimicrobial properties of cytosine &#946;-D-riboside derivatives through molecular dynamics and molecular docking exploration with bacterial and fungal proteins</article-title><source>Asp. Mol. Med.</source><year>2025</year><volume>5</volume><fpage>100077</fpage><pub-id pub-id-type="doi">10.1016/j.amolm.2025.100077</pub-id></element-citation></ref><ref id="B80-molecules-30-03598"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Matsuda</surname><given-names>A.</given-names></name><name name-style="western"><surname>Sasaki</surname><given-names>T.</given-names></name></person-group><article-title>Antitumor activity of sugar-modified cytosine nucleosides</article-title><source>Cancer Sci.</source><year>2004</year><volume>95</volume><fpage>105</fpage><lpage>111</lpage><pub-id pub-id-type="doi">10.1111/j.1349-7006.2004.tb03189.x</pub-id><pub-id pub-id-type="pmid">14965358</pub-id><pub-id pub-id-type="pmcid">PMC11159627</pub-id></element-citation></ref><ref id="B81-molecules-30-03598"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Hickey</surname><given-names>R.J.</given-names></name><name name-style="western"><surname>Malkas</surname><given-names>L.H.</given-names></name></person-group><article-title>Therapeutic Targeting of DNA Replication Stress in Cancer</article-title><source>Genes</source><year>2023</year><volume>14</volume><elocation-id>1346</elocation-id><pub-id pub-id-type="doi">10.3390/genes14071346</pub-id><pub-id pub-id-type="pmid">37510250</pub-id><pub-id pub-id-type="pmcid">PMC10378776</pub-id></element-citation></ref><ref id="B82-molecules-30-03598"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Camcioglu</surname><given-names>S.</given-names></name><name name-style="western"><surname>&#214;zyurt</surname><given-names>B.</given-names></name><name name-style="western"><surname>Oturan</surname><given-names>N.</given-names></name><name name-style="western"><surname>Trellu</surname><given-names>C.</given-names></name><name name-style="western"><surname>Oturan</surname><given-names>M.A.</given-names></name></person-group><article-title>Fast and Complete Destruction of the Anti-Cancer Drug Cytarabine from Water by Electrocatalytic Oxidation Using Electro-Fenton Process</article-title><source>Catalysts</source><year>2022</year><volume>12</volume><elocation-id>1598</elocation-id><pub-id pub-id-type="doi">10.3390/catal12121598</pub-id></element-citation></ref><ref id="B83-molecules-30-03598"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Serhan</surname><given-names>N.</given-names></name><name name-style="western"><surname>Mouchel</surname><given-names>P.-L.</given-names></name><name name-style="western"><surname>de Medina</surname><given-names>P.</given-names></name><name name-style="western"><surname>Segala</surname><given-names>G.</given-names></name><name name-style="western"><surname>Mougel</surname><given-names>A.</given-names></name><name name-style="western"><surname>Saland</surname><given-names>E.</given-names></name><name name-style="western"><surname>Rives</surname><given-names>A.</given-names></name><name name-style="western"><surname>Lamaziere</surname><given-names>A.</given-names></name><name name-style="western"><surname>Despres</surname><given-names>G.</given-names></name><name name-style="western"><surname>Sarry</surname><given-names>J.-E.</given-names></name><etal/></person-group><article-title>Dendrogenin A Synergizes with Cytarabine to Kill Acute Myeloid Leukemia Cells In Vitro and In Vivo</article-title><source>Cancers</source><year>2020</year><volume>12</volume><elocation-id>1725</elocation-id><pub-id pub-id-type="doi">10.3390/cancers12071725</pub-id><pub-id pub-id-type="pmid">32610562</pub-id><pub-id pub-id-type="pmcid">PMC7407291</pub-id></element-citation></ref><ref id="B84-molecules-30-03598"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rupavarshini</surname><given-names>M.</given-names></name><name name-style="western"><surname>Karthikeyan</surname><given-names>S.</given-names></name><name name-style="western"><surname>Anandh</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ramamoorthi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ramakrishnamurthy</surname><given-names>S.</given-names></name><name name-style="western"><surname>Bharanidharan</surname><given-names>G.</given-names></name><name name-style="western"><surname>Aruna</surname><given-names>P.</given-names></name><name name-style="western"><surname>Mangaiyarkarasi</surname><given-names>R.</given-names></name><name name-style="western"><surname>Chinnathambi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Pandian</surname><given-names>G.N.</given-names></name><etal/></person-group><article-title>A biophysical approach of cytarabine anticancer drug insights into human serum albumin and checkpoint kinase 1</article-title><source>Results Chem.</source><year>2023</year><volume>5</volume><fpage>100755</fpage><pub-id pub-id-type="doi">10.1016/j.rechem.2022.100755</pub-id></element-citation></ref><ref id="B85-molecules-30-03598"><label>85.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Di Francia</surname><given-names>R.</given-names></name><name name-style="western"><surname>Crisci</surname><given-names>S.</given-names></name><name name-style="western"><surname>De Monaco</surname><given-names>A.</given-names></name><name name-style="western"><surname>Cafiero</surname><given-names>C.</given-names></name><name name-style="western"><surname>Re</surname><given-names>A.</given-names></name><name name-style="western"><surname>Iaccarino</surname><given-names>G.</given-names></name><name name-style="western"><surname>De Filippi</surname><given-names>R.</given-names></name><name name-style="western"><surname>Frigeri</surname><given-names>F.</given-names></name><name name-style="western"><surname>Corazzelli</surname><given-names>G.</given-names></name><name name-style="western"><surname>Micera</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Response and Toxicity to Cytarabine Therapy in Leukemia and Lymphoma: From Dose Puzzle to Pharmacogenomic Biomarkers</article-title><source>Cancers</source><year>2021</year><volume>13</volume><elocation-id>966</elocation-id><pub-id pub-id-type="doi">10.3390/cancers13050966</pub-id><pub-id pub-id-type="pmid">33669053</pub-id><pub-id pub-id-type="pmcid">PMC7956511</pub-id></element-citation></ref><ref id="B86-molecules-30-03598"><label>86.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sun</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Hao</surname><given-names>K.</given-names></name></person-group><article-title>A Pharmacokinetic and Pharmacodynamic Evaluation of the Anti-Hepatocellular Carcinoma Compound 4-N-Carbobenzoxy-gemcitabine (Cbz-dFdC)</article-title><source>Molecules</source><year>2020</year><volume>25</volume><elocation-id>2218</elocation-id><pub-id pub-id-type="doi">10.3390/molecules25092218</pub-id><pub-id pub-id-type="pmid">32397338</pub-id><pub-id pub-id-type="pmcid">PMC7248705</pub-id></element-citation></ref><ref id="B87-molecules-30-03598"><label>87.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hawry&#322;kiewicz</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ptaszy&#324;ska</surname><given-names>N.</given-names></name></person-group><article-title>Gemcitabine Peptide-Based Conjugates and Their Application in Targeted Tumor Therapy</article-title><source>Molecules</source><year>2021</year><volume>26</volume><elocation-id>364</elocation-id><pub-id pub-id-type="doi">10.3390/molecules26020364</pub-id><pub-id pub-id-type="pmid">33445797</pub-id><pub-id pub-id-type="pmcid">PMC7828243</pub-id></element-citation></ref><ref id="B88-molecules-30-03598"><label>88.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ciccolini</surname><given-names>J.</given-names></name><name name-style="western"><surname>Serdjebi</surname><given-names>C.</given-names></name><name name-style="western"><surname>Peters</surname><given-names>G.J.</given-names></name><name name-style="western"><surname>Giovannetti</surname><given-names>E.</given-names></name></person-group><article-title>Pharmacokinetics and pharmacogenetics of Gemcitabine as a mainstay in adult and pediatric oncology: An EORTC-PAMM perspective</article-title><source>Cancer Chemother. Pharmacol.</source><year>2016</year><volume>78</volume><fpage>1</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.1007/s00280-016-3003-0</pub-id><pub-id pub-id-type="pmid">27007129</pub-id><pub-id pub-id-type="pmcid">PMC4921117</pub-id></element-citation></ref><ref id="B89-molecules-30-03598"><label>89.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Samanta</surname><given-names>K.</given-names></name><name name-style="western"><surname>Setua</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kumari</surname><given-names>S.</given-names></name><name name-style="western"><surname>Jaggi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Yallapu</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Chauhan</surname><given-names>S.C.</given-names></name></person-group><article-title>Gemcitabine Combination Nano Therapies for Pancreatic Cancer</article-title><source>Pharmaceutics</source><year>2019</year><volume>11</volume><elocation-id>574</elocation-id><pub-id pub-id-type="doi">10.3390/pharmaceutics11110574</pub-id><pub-id pub-id-type="pmid">31689930</pub-id><pub-id pub-id-type="pmcid">PMC6920852</pub-id></element-citation></ref><ref id="B90-molecules-30-03598"><label>90.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pandit</surname><given-names>B.</given-names></name><name name-style="western"><surname>Royzen</surname><given-names>M.</given-names></name></person-group><article-title>Recent Development of Prodrugs of Gemcitabine</article-title><source>Genes</source><year>2022</year><volume>13</volume><elocation-id>466</elocation-id><pub-id pub-id-type="doi">10.3390/genes13030466</pub-id><pub-id pub-id-type="pmid">35328020</pub-id><pub-id pub-id-type="pmcid">PMC8954202</pub-id></element-citation></ref><ref id="B91-molecules-30-03598"><label>91.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>D.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>P.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Xing</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Xiao</surname><given-names>Y.</given-names></name></person-group><article-title>NXPH4 Promotes Gemcitabine Resistance in Bladder Cancer by Enhancing Reactive Oxygen Species and Glycolysis Activation through Modulating NDUFA4L2</article-title><source>Cancers</source><year>2022</year><volume>14</volume><elocation-id>3782</elocation-id><pub-id pub-id-type="doi">10.3390/cancers14153782</pub-id><pub-id pub-id-type="pmid">35954445</pub-id><pub-id pub-id-type="pmcid">PMC9367313</pub-id></element-citation></ref><ref id="B92-molecules-30-03598"><label>92.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Momparler</surname><given-names>R.L.</given-names></name></person-group><article-title>A Perspective on the Comparative Antileukemic Activity of 5-Aza-2&#8242;-deoxycytidine (Decitabine) and 5-Azacytidine (Vidaza)</article-title><source>Pharmaceuticals</source><year>2012</year><volume>5</volume><fpage>875</fpage><lpage>881</lpage><pub-id pub-id-type="doi">10.3390/ph5080875</pub-id><pub-id pub-id-type="pmid">24280679</pub-id><pub-id pub-id-type="pmcid">PMC3763670</pub-id></element-citation></ref><ref id="B93-molecules-30-03598"><label>93.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Petralia</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>Mazzon</surname><given-names>E.</given-names></name><name name-style="western"><surname>Basile</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Cutuli</surname><given-names>M.</given-names></name><name name-style="western"><surname>Di Marco</surname><given-names>R.</given-names></name><name name-style="western"><surname>Scandurra</surname><given-names>F.</given-names></name><name name-style="western"><surname>Saraceno</surname><given-names>A.</given-names></name><name name-style="western"><surname>Fagone</surname><given-names>P.</given-names></name><name name-style="western"><surname>Nicoletti</surname><given-names>F.</given-names></name><name name-style="western"><surname>Mangano</surname><given-names>K.</given-names></name></person-group><article-title>Effects of Treatment with the Hypomethylating Agent 5-aza-2&#8242;-deoxycytidine in Murine Type II Collagen-Induced Arthritis</article-title><source>Pharmaceuticals</source><year>2019</year><volume>12</volume><elocation-id>174</elocation-id><pub-id pub-id-type="doi">10.3390/ph12040174</pub-id><pub-id pub-id-type="pmid">31783688</pub-id><pub-id pub-id-type="pmcid">PMC6958460</pub-id></element-citation></ref><ref id="B94-molecules-30-03598"><label>94.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Salehi</surname><given-names>B.</given-names></name><name name-style="western"><surname>Selamoglu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Mileski</surname><given-names>K.S.</given-names></name><name name-style="western"><surname>Pezzani</surname><given-names>R.</given-names></name><name name-style="western"><surname>Redaelli</surname><given-names>M.</given-names></name><name name-style="western"><surname>Cho</surname><given-names>W.C.</given-names></name><name name-style="western"><surname>Kobarfard</surname><given-names>F.</given-names></name><name name-style="western"><surname>Rajabi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Martorell</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kumar</surname><given-names>P.</given-names></name><etal/></person-group><article-title>Liposomal Cytarabine as Cancer Therapy: From Chemistry to Medicine</article-title><source>Biomolecules</source><year>2019</year><volume>9</volume><elocation-id>773</elocation-id><pub-id pub-id-type="doi">10.3390/biom9120773</pub-id><pub-id pub-id-type="pmid">31771220</pub-id><pub-id pub-id-type="pmcid">PMC6995526</pub-id></element-citation></ref><ref id="B95-molecules-30-03598"><label>95.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Etrych</surname><given-names>T.</given-names></name><name name-style="western"><surname>Braunova</surname><given-names>A.</given-names></name><name name-style="western"><surname>Zogala</surname><given-names>D.</given-names></name><name name-style="western"><surname>Lambert</surname><given-names>L.</given-names></name><name name-style="western"><surname>Renesova</surname><given-names>N.</given-names></name><name name-style="western"><surname>Klener</surname><given-names>P.</given-names></name></person-group><article-title>Targeted Drug Delivery and Theranostic Strategies in Malignant Lymphomas</article-title><source>Cancers</source><year>2022</year><volume>14</volume><elocation-id>626</elocation-id><pub-id pub-id-type="doi">10.3390/cancers14030626</pub-id><pub-id pub-id-type="pmid">35158894</pub-id><pub-id pub-id-type="pmcid">PMC8833783</pub-id></element-citation></ref><ref id="B96-molecules-30-03598"><label>96.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sarkisjan</surname><given-names>D.</given-names></name><name name-style="western"><surname>Julsing</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>Smid</surname><given-names>K.</given-names></name><name name-style="western"><surname>de Klerk</surname><given-names>D.</given-names></name><name name-style="western"><surname>van Kuilenburg</surname><given-names>A.B.P.</given-names></name><name name-style="western"><surname>Meinsma</surname><given-names>R.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>Y.B.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>D.</given-names></name><name name-style="western"><surname>Peters</surname><given-names>G.J.</given-names></name></person-group><article-title>The Cytidine Analog Fluorocyclopentenylcy-tosine (RX-3117) Is Activated by Uridine-Cytidine Kinase 2</article-title><source>PLoS ONE</source><year>2016</year><volume>11</volume><elocation-id>e0162901</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0162901</pub-id><pub-id pub-id-type="pmid">27612203</pub-id><pub-id pub-id-type="pmcid">PMC5017758</pub-id></element-citation></ref><ref id="B97-molecules-30-03598"><label>97.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>K.-H.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>N.D.</given-names></name><name name-style="western"><surname>Seong</surname><given-names>B.-L.</given-names></name></person-group><article-title>Discovery and Development of Anti-HBV Agents and Their Resistance</article-title><source>Molecules</source><year>2010</year><volume>15</volume><fpage>5878</fpage><lpage>5908</lpage><pub-id pub-id-type="doi">10.3390/molecules15095878</pub-id><pub-id pub-id-type="pmid">20802402</pub-id><pub-id pub-id-type="pmcid">PMC6257723</pub-id></element-citation></ref><ref id="B98-molecules-30-03598"><label>98.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sever</surname><given-names>B.</given-names></name><name name-style="western"><surname>Otsuka</surname><given-names>M.</given-names></name><name name-style="western"><surname>Fujita</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ciftci</surname><given-names>H.</given-names></name></person-group><article-title>A Review of FDA-Approved Anti-HIV-1 Drugs, Anti-Gag Compounds, and Potential Strategies for HIV-1 Eradication</article-title><source>Int. J. Mol. Sci.</source><year>2024</year><volume>25</volume><elocation-id>3659</elocation-id><pub-id pub-id-type="doi">10.3390/ijms25073659</pub-id><pub-id pub-id-type="pmid">38612471</pub-id><pub-id pub-id-type="pmcid">PMC11012182</pub-id></element-citation></ref><ref id="B99-molecules-30-03598"><label>99.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mimtsoudis</surname><given-names>I.</given-names></name><name name-style="western"><surname>Tsachouridou</surname><given-names>O.</given-names></name><name name-style="western"><surname>Akinosoglou</surname><given-names>K.</given-names></name><name name-style="western"><surname>Metallidis</surname><given-names>S.</given-names></name></person-group><article-title>Treatment Management Challenges in Na&#239;ve and Experienced HIV-1-Infected Individuals Carrying the M184V Mutation</article-title><source>Viruses</source><year>2024</year><volume>16</volume><elocation-id>1392</elocation-id><pub-id pub-id-type="doi">10.3390/v16091392</pub-id><pub-id pub-id-type="pmid">39339868</pub-id><pub-id pub-id-type="pmcid">PMC11437411</pub-id></element-citation></ref><ref id="B100-molecules-30-03598"><label>100.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Andrei</surname><given-names>G.</given-names></name><name name-style="western"><surname>Snoeck</surname><given-names>R.</given-names></name></person-group><article-title>Cidofovir Activity against Poxvirus Infections</article-title><source>Viruses</source><year>2010</year><volume>2</volume><fpage>2803</fpage><lpage>2830</lpage><pub-id pub-id-type="doi">10.3390/v2122803</pub-id><pub-id pub-id-type="pmid">21994641</pub-id><pub-id pub-id-type="pmcid">PMC3185586</pub-id></element-citation></ref><ref id="B101-molecules-30-03598"><label>101.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Waye</surname><given-names>M.M.Y.</given-names></name><name name-style="western"><surname>Sing</surname><given-names>C.W.</given-names></name></person-group><article-title>Anti-Viral Drugs for Human Adenoviruses</article-title><source>Pharmaceuticals</source><year>2010</year><volume>3</volume><fpage>3343</fpage><lpage>3354</lpage><pub-id pub-id-type="doi">10.3390/ph3103343</pub-id></element-citation></ref><ref id="B102-molecules-30-03598"><label>102.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Teli</surname><given-names>D.</given-names></name><name name-style="western"><surname>Balar</surname><given-names>P.</given-names></name><name name-style="western"><surname>Patel</surname><given-names>K.</given-names></name><name name-style="western"><surname>Sharma</surname><given-names>A.</given-names></name><name name-style="western"><surname>Chavda</surname><given-names>V.</given-names></name><name name-style="western"><surname>Vora</surname><given-names>L.</given-names></name></person-group><article-title>Molnupiravir: A Versatile Prodrug against SARS-CoV-2 Variants</article-title><source>Metabolites</source><year>2023</year><volume>13</volume><elocation-id>309</elocation-id><pub-id pub-id-type="doi">10.3390/metabo13020309</pub-id><pub-id pub-id-type="pmid">36837928</pub-id><pub-id pub-id-type="pmcid">PMC9962121</pub-id></element-citation></ref><ref id="B103-molecules-30-03598"><label>103.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bakos</surname><given-names>&#201;.</given-names></name><name name-style="western"><surname>Temesszentandr&#225;si-Ambrus</surname><given-names>C.</given-names></name><name name-style="western"><surname>&#214;zvegy-Laczka</surname><given-names>C.</given-names></name><name name-style="western"><surname>G&#225;borik</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Sarkadi</surname><given-names>B.</given-names></name><name name-style="western"><surname>Telbisz</surname><given-names>&#193;.</given-names></name></person-group><article-title>Interactions of the Anti-SARS-CoV-2 Agents Molnupiravir and Nirmatrelvir/Paxlovid with Human Drug Transporters</article-title><source>Int. J. Mol. Sci.</source><year>2023</year><volume>24</volume><elocation-id>11237</elocation-id><pub-id pub-id-type="doi">10.3390/ijms241411237</pub-id><pub-id pub-id-type="pmid">37510996</pub-id><pub-id pub-id-type="pmcid">PMC10379611</pub-id></element-citation></ref><ref id="B104-molecules-30-03598"><label>104.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Maple</surname><given-names>P.A.C.</given-names></name><name name-style="western"><surname>Hosseini</surname><given-names>A.A.</given-names></name></person-group><article-title>Human Alpha Herpesviruses Infections (HSV1, HSV2, and VZV), Alzheimer&#8217;s Disease, and the Potential Benefits of Targeted Treatment or Vaccination&#8212;A Virological Perspective</article-title><source>Vaccines</source><year>2025</year><volume>13</volume><elocation-id>572</elocation-id><pub-id pub-id-type="doi">10.3390/vaccines13060572</pub-id><pub-id pub-id-type="pmid">40573903</pub-id><pub-id pub-id-type="pmcid">PMC12197456</pub-id></element-citation></ref><ref id="B105-molecules-30-03598"><label>105.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Majewska</surname><given-names>A.</given-names></name><name name-style="western"><surname>Mlynarczyk-Bonikowska</surname><given-names>B.</given-names></name></person-group><article-title>40 Years after the Registration of Acyclovir: Do We Need New Anti-Herpetic Drugs?</article-title><source>Int. J. Mol. Sci.</source><year>2022</year><volume>23</volume><elocation-id>3431</elocation-id><pub-id pub-id-type="doi">10.3390/ijms23073431</pub-id><pub-id pub-id-type="pmid">35408788</pub-id><pub-id pub-id-type="pmcid">PMC8998721</pub-id></element-citation></ref><ref id="B106-molecules-30-03598"><label>106.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lenarczyk</surname><given-names>E.</given-names></name><name name-style="western"><surname>Oleksiak</surname><given-names>D.</given-names></name><name name-style="western"><surname>Janeczko</surname><given-names>M.</given-names></name></person-group><article-title>Antifungal Activity of 5-Fluorouridine Against <italic toggle="yes">Candida albicans</italic> and <italic toggle="yes">Candida parapsilosis</italic> Based on Virulence Reduction</article-title><source>Molecules</source><year>2025</year><volume>30</volume><elocation-id>2735</elocation-id><pub-id pub-id-type="doi">10.3390/molecules30132735</pub-id><pub-id pub-id-type="pmid">40649252</pub-id><pub-id pub-id-type="pmcid">PMC12250778</pub-id></element-citation></ref><ref id="B107-molecules-30-03598"><label>107.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hetta</surname><given-names>H.F.</given-names></name><name name-style="western"><surname>Melhem</surname><given-names>T.</given-names></name><name name-style="western"><surname>Aljohani</surname><given-names>H.M.</given-names></name><name name-style="western"><surname>Salama</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ahmed</surname><given-names>R.</given-names></name><name name-style="western"><surname>Elfadil</surname><given-names>H.</given-names></name><name name-style="western"><surname>Alanazi</surname><given-names>F.E.</given-names></name><name name-style="western"><surname>Ramadan</surname><given-names>Y.N.</given-names></name><name name-style="western"><surname>Battah</surname><given-names>B.</given-names></name><name name-style="western"><surname>Rottura</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Beyond Conventional Antifungals: Combating Resistance Through Novel Therapeutic Pathways</article-title><source>Pharmaceuticals</source><year>2025</year><volume>18</volume><elocation-id>364</elocation-id><pub-id pub-id-type="doi">10.3390/ph18030364</pub-id><pub-id pub-id-type="pmid">40143141</pub-id><pub-id pub-id-type="pmcid">PMC11944814</pub-id></element-citation></ref><ref id="B108-molecules-30-03598"><label>108.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Spadari</surname><given-names>C.d.C.</given-names></name><name name-style="western"><surname>Wirth</surname><given-names>F.</given-names></name><name name-style="western"><surname>Lopes</surname><given-names>L.B.</given-names></name><name name-style="western"><surname>Ishida</surname><given-names>K.</given-names></name></person-group><article-title>New Approaches for Cryptococcosis Treatment</article-title><source>Microorganisms</source><year>2020</year><volume>8</volume><elocation-id>613</elocation-id><pub-id pub-id-type="doi">10.3390/microorganisms8040613</pub-id><pub-id pub-id-type="pmid">32340403</pub-id><pub-id pub-id-type="pmcid">PMC7232457</pub-id></element-citation></ref><ref id="B109-molecules-30-03598"><label>109.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Melhem</surname><given-names>M.S.C.</given-names></name><name name-style="western"><surname>Leite J&#250;nior</surname><given-names>D.P.</given-names></name><name name-style="western"><surname>Takahashi</surname><given-names>J.P.F.</given-names></name><name name-style="western"><surname>Macioni</surname><given-names>M.B.</given-names></name><name name-style="western"><surname>Oliveira</surname><given-names>L.d.</given-names></name><name name-style="western"><surname>de Ara&#250;jo</surname><given-names>L.S.</given-names></name><name name-style="western"><surname>Fava</surname><given-names>W.S.</given-names></name><name name-style="western"><surname>Bonfietti</surname><given-names>L.X.</given-names></name><name name-style="western"><surname>Paniago</surname><given-names>A.M.M.</given-names></name><name name-style="western"><surname>Venturini</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Antifungal Resistance in Cryptococcal Infections</article-title><source>Pathogens</source><year>2024</year><volume>13</volume><elocation-id>128</elocation-id><pub-id pub-id-type="doi">10.3390/pathogens13020128</pub-id><pub-id pub-id-type="pmid">38392866</pub-id><pub-id pub-id-type="pmcid">PMC10891860</pub-id></element-citation></ref><ref id="B110-molecules-30-03598"><label>110.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Grieb</surname><given-names>B.</given-names></name></person-group><article-title>Neuroprotective Properties of Citicoline: Facts, Doubts and Unresolved Issues</article-title><source>CNS Drugs</source><year>2014</year><volume>28</volume><fpage>185</fpage><lpage>193</lpage><pub-id pub-id-type="doi">10.1007/s40263-014-0144-8</pub-id><pub-id pub-id-type="pmid">24504829</pub-id><pub-id pub-id-type="pmcid">PMC3933742</pub-id></element-citation></ref><ref id="B111-molecules-30-03598"><label>111.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lyu</surname><given-names>W.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>H.</given-names></name></person-group><article-title>Carmofur Exhibits Antimicrobial Activity Against Streptococcus pneumoniae</article-title><source>Antibiotics</source><year>2025</year><volume>14</volume><elocation-id>231</elocation-id><pub-id pub-id-type="doi">10.3390/antibiotics14030231</pub-id><pub-id pub-id-type="pmid">40149043</pub-id><pub-id pub-id-type="pmcid">PMC11939412</pub-id></element-citation></ref><ref id="B112-molecules-30-03598"><label>112.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Manska</surname><given-names>S.</given-names></name><name name-style="western"><surname>Octaviano</surname><given-names>R.</given-names></name><name name-style="western"><surname>Rossetto</surname><given-names>C.C.</given-names></name></person-group><article-title>5-Ethynyl-2&#8242;-deoxycytidine and 5-ethynyl-2&#8242;-deoxyuridine are differentially incorporated in cells infected with HSV-1, HCMV, and KSHV viruses</article-title><source>J. Biol. Chem.</source><year>2020</year><volume>295</volume><fpage>5871</fpage><lpage>5890</lpage><pub-id pub-id-type="doi">10.1074/jbc.RA119.012378</pub-id><pub-id pub-id-type="pmid">32205447</pub-id><pub-id pub-id-type="pmcid">PMC7196651</pub-id></element-citation></ref><ref id="B113-molecules-30-03598"><label>113.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Qu</surname><given-names>D.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>G.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>L.</given-names></name><name name-style="western"><surname>Chi</surname><given-names>W.</given-names></name><name name-style="western"><surname>Cong</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ren</surname><given-names>X.</given-names></name><name name-style="western"><surname>Liang</surname><given-names>P.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>B.</given-names></name></person-group><article-title>5-Ethynyl-2&#8242;-deoxycytidine as a new agent for DNA labeling: Detection of proliferating cells</article-title><source>Anal. Biochem.</source><year>2011</year><volume>417</volume><fpage>112</fpage><lpage>121</lpage><pub-id pub-id-type="doi">10.1016/j.ab.2011.05.037</pub-id><pub-id pub-id-type="pmid">21683679</pub-id></element-citation></ref><ref id="B114-molecules-30-03598"><label>114.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chillar</surname><given-names>K.</given-names></name><name name-style="western"><surname>Awasthy</surname><given-names>R.</given-names></name><name name-style="western"><surname>Tanasova</surname><given-names>M.</given-names></name><name name-style="western"><surname>Fang</surname><given-names>S.</given-names></name></person-group><article-title>Synthesis of Sensitive Oligodeoxynucleotides Containing Acylated Cytosine, Adenine, and Guanine Nucleobases</article-title><source>DNA</source><year>2025</year><volume>5</volume><elocation-id>25</elocation-id><pub-id pub-id-type="doi">10.3390/dna5020025</pub-id><pub-id pub-id-type="pmid">40709081</pub-id><pub-id pub-id-type="pmcid">PMC12288508</pub-id></element-citation></ref><ref id="B115-molecules-30-03598"><label>115.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>P.</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>T.</given-names></name><name name-style="western"><surname>Pan</surname><given-names>J.</given-names></name></person-group><article-title>Nucleoside Analogs: A Review of Its Source and Separation Processes</article-title><source>Molecules</source><year>2023</year><volume>28</volume><elocation-id>7043</elocation-id><pub-id pub-id-type="doi">10.3390/molecules28207043</pub-id><pub-id pub-id-type="pmid">37894522</pub-id><pub-id pub-id-type="pmcid">PMC10608831</pub-id></element-citation></ref><ref id="B116-molecules-30-03598"><label>116.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Huang</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Kaiser</surname><given-names>K.</given-names></name><name name-style="western"><surname>Benne</surname><given-names>R.</given-names></name></person-group><article-title>A simple high performance liquid chromatography method for the measurement of nucleobases and the RNA and DNA content of cellular material</article-title><source>Limnol. Oceanogr. Methods</source><year>2012</year><volume>10</volume><fpage>608</fpage><lpage>616</lpage><pub-id pub-id-type="doi">10.4319/lom.2012.10.608</pub-id></element-citation></ref><ref id="B117-molecules-30-03598"><label>117.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yin</surname><given-names>R.</given-names></name><name name-style="western"><surname>Mo</surname><given-names>J.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>M.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H.</given-names></name></person-group><article-title>Detection of human urinary 5-hydroxymethylcytosine by Stable isotope dilution HPLC-MS/MS analysis</article-title><source>Anal. Chem.</source><year>2015</year><volume>87</volume><fpage>1846</fpage><lpage>1852</lpage><pub-id pub-id-type="doi">10.1021/ac5038895</pub-id><pub-id pub-id-type="pmid">25551771</pub-id></element-citation></ref><ref id="B118-molecules-30-03598"><label>118.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Young</surname><given-names>L.</given-names></name><name name-style="western"><surname>Leng</surname><given-names>A.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Xue</surname><given-names>Y.</given-names></name></person-group><article-title>A Practical Method for Determination of Nine Nucleosides in <italic toggle="yes">Tricholoma matsutake</italic> by UPLC/MS and Quantitative Analysis of Multicomponents Using Single Marker Method</article-title><source>J. Anal. Methods Chem.</source><year>2021</year><volume>2021</volume><fpage>1</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.1155/2021/9571329</pub-id><pub-id pub-id-type="pmcid">PMC8452435</pub-id><pub-id pub-id-type="pmid">34552805</pub-id></element-citation></ref><ref id="B119-molecules-30-03598"><label>119.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Andrus</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kuimelis</surname><given-names>R.G.</given-names></name></person-group><article-title>Base Composition Analysis of Nucleosides Using HPLC</article-title><source>Curr. Protoc. Nucleic Acid. Chem.</source><year>2001</year><volume>10</volume><fpage>10.6</fpage><pub-id pub-id-type="doi">10.1002/0471142700.nc1006s01</pub-id><pub-id pub-id-type="pmid">18428825</pub-id></element-citation></ref><ref id="B120-molecules-30-03598"><label>120.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Roberts</surname><given-names>C.E.</given-names></name><name name-style="western"><surname>Raner</surname><given-names>G.M.</given-names></name><name name-style="western"><surname>Isaacs</surname><given-names>G.D.</given-names></name></person-group><article-title>High Performance Liquid Chromatography Separation of Epigenetic Cytosine Variants</article-title><source>Methods Protoc.</source><year>2018</year><volume>1</volume><elocation-id>10</elocation-id><pub-id pub-id-type="doi">10.3390/mps1020010</pub-id><pub-id pub-id-type="pmid">31164555</pub-id><pub-id pub-id-type="pmcid">PMC6526450</pub-id></element-citation></ref><ref id="B121-molecules-30-03598"><label>121.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tuytten</surname><given-names>R.</given-names></name><name name-style="western"><surname>Lemi&#232;re</surname><given-names>F.</given-names></name><name name-style="western"><surname>Van Dongen</surname><given-names>W.</given-names></name><name name-style="western"><surname>Witters</surname><given-names>E.</given-names></name><name name-style="western"><surname>Esmans</surname><given-names>E.L.</given-names></name><name name-style="western"><surname>Newton</surname><given-names>R.P.</given-names></name><name name-style="western"><surname>Dudley</surname><given-names>E.</given-names></name></person-group><article-title>Development of an On-Line SPE-LC&#8211;ESI-MS Method for Urinary Nucleosides:&#8201; Hyphenation of Aprotic Boronic Acid Chromatography with Hydrophilic Interaction LC&#8211;ESI-MS</article-title><source>Anal. Chem.</source><year>2008</year><volume>80</volume><fpage>1263</fpage><lpage>1271</lpage><pub-id pub-id-type="doi">10.1021/ac702057u</pub-id><pub-id pub-id-type="pmid">18198895</pub-id></element-citation></ref><ref id="B122-molecules-30-03598"><label>122.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kluska</surname><given-names>M.</given-names></name><name name-style="western"><surname>Pypowski</surname><given-names>K.</given-names></name><name name-style="western"><surname>Chrz&#261;&#347;cik</surname><given-names>I.</given-names></name><name name-style="western"><surname>Koval</surname><given-names>T.</given-names></name><name name-style="western"><surname>Erchak</surname><given-names>N.</given-names></name></person-group><article-title>Separation and Determination of Chosen &#955;5-Silanates by an Isotachophoresis Technique</article-title><source>J. Liq. Chromatogr. Relat. Technol.</source><year>2009</year><volume>32</volume><fpage>896</fpage><lpage>907</lpage><pub-id pub-id-type="doi">10.1080/10826070902768187</pub-id></element-citation></ref><ref id="B123-molecules-30-03598"><label>123.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pruka&#322;a</surname><given-names>W.</given-names></name><name name-style="western"><surname>Pypowski</surname><given-names>K.</given-names></name><name name-style="western"><surname>Chrz&#261;&#347;cik</surname><given-names>I.</given-names></name><name name-style="western"><surname>Kluska</surname><given-names>M.</given-names></name></person-group><article-title>Separation of Biologically Active Isomers of (E)-N-Meta- and Para-Nitroazastilbenes by the HPLC Technique</article-title><source>J. Liq. Chromatogr. Relat. Technol.</source><year>2008</year><volume>31</volume><fpage>578</fpage><lpage>585</lpage><pub-id pub-id-type="doi">10.1080/01630560701815218</pub-id></element-citation></ref><ref id="B124-molecules-30-03598"><label>124.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pruka&#322;a</surname><given-names>W.</given-names></name><name name-style="western"><surname>Pruka&#322;a</surname><given-names>D.</given-names></name><name name-style="western"><surname>Pypowski</surname><given-names>K.</given-names></name><name name-style="western"><surname>Chrz&#261;&#347;cik</surname><given-names>I.</given-names></name><name name-style="western"><surname>Kluska</surname><given-names>M.</given-names></name></person-group><article-title>Chromatography of Biologically Active Chlorides of (<italic toggle="yes">E</italic>)-N-<italic toggle="yes">o</italic>-(<italic toggle="yes">m</italic>- or <italic toggle="yes">p</italic>-)chlorobenzyl-&#947;-azastilbenols-2&#8242;(3&#8242; or 4&#8242;)</article-title><source>J. Liq. Chromatogr. Relat. Technol.</source><year>2008</year><volume>31</volume><fpage>2612</fpage><lpage>2620</lpage><pub-id pub-id-type="doi">10.1080/10826070802352850</pub-id></element-citation></ref><ref id="B125-molecules-30-03598"><label>125.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kluska</surname><given-names>M.</given-names></name><name name-style="western"><surname>Pypowski</surname><given-names>K.</given-names></name><name name-style="western"><surname>Erchak</surname><given-names>N.</given-names></name></person-group><article-title>Separation of Hexabenzyldigermoxane and Hexabenzyldigermanium by HPLC</article-title><source>J. Liq. Chromatogr. Relat. Technol.</source><year>2007</year><volume>30</volume><fpage>1777</fpage><lpage>1785</lpage><pub-id pub-id-type="doi">10.1080/10826070701360418</pub-id></element-citation></ref><ref id="B126-molecules-30-03598"><label>126.</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Russell</surname><given-names>J.J.</given-names></name></person-group><article-title>Development of Generic Methods for the Analysis and Purification of Polar Compounds by High Performance Liquid Chromatography</article-title><source>Ph.D. Thesis</source><publisher-name>University of the West of England</publisher-name><publisher-loc>Bristol, UK</publisher-loc><year>2016</year></element-citation></ref><ref id="B127-molecules-30-03598"><label>127.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kisil</surname><given-names>O.</given-names></name><name name-style="western"><surname>Sergeev</surname><given-names>A.</given-names></name><name name-style="western"><surname>Bacheva</surname><given-names>A.</given-names></name><name name-style="western"><surname>Zvereva</surname><given-names>M.</given-names></name></person-group><article-title>Methods for Detection and Mapping of Methylated and Hydroxymethylated Cytosine in DNA</article-title><source>Biomolecules</source><year>2024</year><volume>14</volume><elocation-id>1346</elocation-id><pub-id pub-id-type="doi">10.3390/biom14111346</pub-id><pub-id pub-id-type="pmid">39595523</pub-id><pub-id pub-id-type="pmcid">PMC11591845</pub-id></element-citation></ref><ref id="B128-molecules-30-03598"><label>128.</label><element-citation publication-type="webpage"><article-title>HPLC Method for Separation of Cytosine, Deoxycytidine and Cytidine on BIST B+ by SIELC Technologies</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://sielc.com/hplc-method-of-cytosine-deoxycytidine-cytidine" ext-link-type="uri">https://sielc.com/hplc-method-of-cytosine-deoxycytidine-cytidine</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2025-06-29">(accessed on 29 June 2025)</date-in-citation></element-citation></ref><ref id="B129-molecules-30-03598"><label>129.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Romanova</surname><given-names>D.</given-names></name><name name-style="western"><surname>Novotny</surname><given-names>L.</given-names></name></person-group><article-title>Chromatographic properties of cytosine, cytidine and their synthetic analogues</article-title><source>J. Chromatogr. B</source><year>1996</year><volume>675</volume><fpage>9</fpage><lpage>15</lpage><pub-id pub-id-type="doi">10.1016/0378-4347(95)00334-7</pub-id><pub-id pub-id-type="pmid">8634774</pub-id></element-citation></ref><ref id="B130-molecules-30-03598"><label>130.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Maga&#241;a</surname><given-names>A.A.</given-names></name><name name-style="western"><surname>Wrobel</surname><given-names>K.</given-names></name><name name-style="western"><surname>Caudillo</surname><given-names>A.C.</given-names></name><name name-style="western"><surname>Luna</surname><given-names>S.Z.</given-names></name><name name-style="western"><surname>Wrobel</surname><given-names>K.</given-names></name></person-group><article-title>High-performance liquid chromatography determination of 5-methyl-2&#8242;-deoxycytidine, 2&#8242;-deoxycytidine, and other deoxynucleosides and nucleosides in DNA digests</article-title><source>Anal. Biochem.</source><year>2008</year><volume>374</volume><fpage>378</fpage><lpage>385</lpage><pub-id pub-id-type="doi">10.1016/j.ab.2007.11.026</pub-id><pub-id pub-id-type="pmid">18157934</pub-id></element-citation></ref><ref id="B131-molecules-30-03598"><label>131.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guo</surname><given-names>J.</given-names></name><name name-style="western"><surname>Turesky</surname><given-names>R.J.</given-names></name></person-group><article-title>Emerging Technologies in Mass Spectrometry-Based DNA Adductomics</article-title><source>High-Throughput</source><year>2019</year><volume>8</volume><elocation-id>13</elocation-id><pub-id pub-id-type="doi">10.3390/ht8020013</pub-id><pub-id pub-id-type="pmid">31091740</pub-id><pub-id pub-id-type="pmcid">PMC6630665</pub-id></element-citation></ref><ref id="B132-molecules-30-03598"><label>132.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Villalta</surname><given-names>P.W.</given-names></name><name name-style="western"><surname>Balbo</surname><given-names>S.</given-names></name></person-group><article-title>The Future of DNA Adductomic Analysis</article-title><source>Int. J. Mol. Sci.</source><year>2017</year><volume>18</volume><elocation-id>1870</elocation-id><pub-id pub-id-type="doi">10.3390/ijms18091870</pub-id><pub-id pub-id-type="pmid">32962318</pub-id><pub-id pub-id-type="pmcid">PMC5618519</pub-id></element-citation></ref><ref id="B133-molecules-30-03598"><label>133.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Honeywell</surname><given-names>R.</given-names></name><name name-style="western"><surname>Laan</surname><given-names>A.C.</given-names></name><name name-style="western"><surname>van Groeningen</surname><given-names>C.J.</given-names></name><name name-style="western"><surname>Strocchi</surname><given-names>E.</given-names></name><name name-style="western"><surname>Ruiter</surname><given-names>R.</given-names></name><name name-style="western"><surname>Gaccone</surname><given-names>G.</given-names></name><name name-style="western"><surname>Peters</surname><given-names>G.J.</given-names></name></person-group><article-title>The determination of gemcitabine and 2&#8242;-deoxycytidine in human plasma and tissue by APCI tandem mass spectrometry</article-title><source>J. Chromatogr. B</source><year>2007</year><volume>847</volume><fpage>142</fpage><lpage>152</lpage><pub-id pub-id-type="doi">10.1016/j.jchromb.2006.09.045</pub-id><pub-id pub-id-type="pmid">17056304</pub-id></element-citation></ref><ref id="B134-molecules-30-03598"><label>134.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pruka&#322;a</surname><given-names>D.</given-names></name></person-group><article-title>Synthesis and physicochemical properties of new 1N <italic toggle="yes">o</italic>-(<italic toggle="yes">m</italic>- and <italic toggle="yes">p</italic>-) bromobenzyl substituted derivatives of 5-(aminodialkyl)methylcytosine</article-title><source>J. Heterocycl. Chem.</source><year>2007</year><volume>44</volume><fpage>1207</fpage><lpage>1212</lpage><pub-id pub-id-type="doi">10.1002/jhet.5570440539</pub-id></element-citation></ref><ref id="B135-molecules-30-03598"><label>135.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kluska</surname><given-names>M.</given-names></name><name name-style="western"><surname>Pruka&#322;a</surname><given-names>D.</given-names></name><name name-style="western"><surname>Pruka&#322;a</surname><given-names>W.</given-names></name><name name-style="western"><surname>Kondrzycka-D&#261;da</surname><given-names>A.</given-names></name><name name-style="western"><surname>Komasi&#324;ska</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ma&#322;kiewicz</surname><given-names>K.</given-names></name></person-group><article-title>Successful Separation And Determination of Isomers of Cytosine Derivatives for HPLC</article-title><source>J. Liq. Chromatogr. Relat. Technol.</source><year>2014</year><volume>37</volume><fpage>2172</fpage><lpage>2181</lpage><pub-id pub-id-type="doi">10.1080/10826076.2013.828304</pub-id></element-citation></ref><ref id="B136-molecules-30-03598"><label>136.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kluska</surname><given-names>M.</given-names></name><name name-style="western"><surname>Liepinsh</surname><given-names>E.</given-names></name><name name-style="western"><surname>Pypowski</surname><given-names>K.</given-names></name><name name-style="western"><surname>Chrz&#261;&#347;cik</surname><given-names>I.</given-names></name><name name-style="western"><surname>Michel</surname><given-names>M.</given-names></name><name name-style="western"><surname>Erchak</surname><given-names>N.</given-names></name></person-group><article-title>Separation of Selected Derivatives of Hoszczawa-Silanates, Taking Advantage of &#960;&#8211;&#960; Interactions</article-title><source>J. Liq. Chromatogr. Relat. Technol.</source><year>2008</year><volume>31</volume><fpage>2812</fpage><lpage>2820</lpage><pub-id pub-id-type="doi">10.1080/10826070802388466</pub-id></element-citation></ref><ref id="B137-molecules-30-03598"><label>137.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kluska</surname><given-names>M.</given-names></name><name name-style="western"><surname>Pypowski</surname><given-names>K.</given-names></name></person-group><article-title>Separation of Tribenzylhydrogermanium Nitrile Derivatives by Means of HPLC with Participation of &#928;-&#928; Interactions</article-title><source>J. Liq. Chromatogr. Relat. Technol.</source><year>2007</year><volume>30</volume><fpage>2059</fpage><lpage>2067</lpage><pub-id pub-id-type="doi">10.1080/10826070701435061</pub-id></element-citation></ref><ref id="B138-molecules-30-03598"><label>138.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pypowski</surname><given-names>K.</given-names></name><name name-style="western"><surname>Uszy&#324;ska</surname><given-names>I.</given-names></name><name name-style="western"><surname>Kluska</surname><given-names>M.</given-names></name></person-group><article-title>Chromatographic Separation of Isomers of Tribenzylgermanium Nitrile Derivatives using Chemically Bonded Aryl Stationary Phases</article-title><source>J. Liq. Chromatogr. Relat. Technol.</source><year>2006</year><volume>29</volume><fpage>2989</fpage><lpage>2996</lpage><pub-id pub-id-type="doi">10.1080/10826070600981157</pub-id></element-citation></ref><ref id="B139-molecules-30-03598"><label>139.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kluska</surname><given-names>M.</given-names></name><name name-style="western"><surname>Liepinsh</surname><given-names>E.</given-names></name><name name-style="western"><surname>Pypowski</surname><given-names>K.</given-names></name><name name-style="western"><surname>Erchak</surname><given-names>N.</given-names></name></person-group><article-title>Separation of Azepinio-Methyl Derivatives of ES-Silanates by the Use of Aryl Stationary Phases in HPLC</article-title><source>J. Liq. Chromatogr. Relat. Technol.</source><year>2008</year><volume>31</volume><fpage>675</fpage><lpage>682</lpage><pub-id pub-id-type="doi">10.1080/10826070701853826</pub-id></element-citation></ref><ref id="B140-molecules-30-03598"><label>140.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kluska</surname><given-names>M.</given-names></name></person-group><article-title>An Application of Aryl Stationary Phases for Separation of Select Organogermanium Compounds</article-title><source>J. Liq. Chromatogr. Relat. Technol.</source><year>2007</year><volume>31</volume><fpage>210</fpage><lpage>218</lpage><pub-id pub-id-type="doi">10.1080/10826070701738845</pub-id></element-citation></ref><ref id="B141-molecules-30-03598"><label>141.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Parys</surname><given-names>W.</given-names></name><name name-style="western"><surname>Do&#322;owy</surname><given-names>M.</given-names></name><name name-style="western"><surname>Pyka-Paj&#261;k</surname><given-names>A.</given-names></name></person-group><article-title>Significance of Chromatographic Techniques in Pharmaceutical Analysis</article-title><source>Processes</source><year>2022</year><volume>10</volume><elocation-id>172</elocation-id><pub-id pub-id-type="doi">10.3390/pr10010172</pub-id></element-citation></ref><ref id="B142-molecules-30-03598"><label>142.</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Berdasco</surname><given-names>M.</given-names></name><name name-style="western"><surname>Fraga</surname><given-names>M.F.</given-names></name><name name-style="western"><surname>Esteller</surname><given-names>M.</given-names></name></person-group><article-title>Quantification of Global DNA Methylation by Capillary Electrophoresis and Mass Spectrometry</article-title><source>DNA Methylation. Methods in Molecular Biology</source><person-group person-group-type="editor"><name name-style="western"><surname>Walker</surname><given-names>J.M.</given-names></name></person-group><publisher-name>Humana Press</publisher-name><publisher-loc>Totowa, NJ, USA</publisher-loc><year>2009</year><volume>Volume 2007</volume><fpage>23</fpage><lpage>34</lpage><pub-id pub-id-type="doi">10.1007/978-1-59745-522-0_2</pub-id><pub-id pub-id-type="pmid">18987803</pub-id></element-citation></ref><ref id="B143-molecules-30-03598"><label>143.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Minhas-Khan</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ghafar-Zadeh</surname><given-names>M.</given-names></name><name name-style="western"><surname>Shaffaf</surname><given-names>T.</given-names></name><name name-style="western"><surname>Forouhi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Scime</surname><given-names>A.</given-names></name><name name-style="western"><surname>Magierowski</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ghafar-Zadeh</surname><given-names>E.</given-names></name></person-group><article-title>UV-Vis Spectrophotometric Analysis of DNA Retrieval for DNA Storage Applications</article-title><source>Actuators</source><year>2021</year><volume>10</volume><elocation-id>246</elocation-id><pub-id pub-id-type="doi">10.3390/act10100246</pub-id></element-citation></ref><ref id="B144-molecules-30-03598"><label>144.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bruijns</surname><given-names>B.</given-names></name><name name-style="western"><surname>Hoekema</surname><given-names>T.</given-names></name><name name-style="western"><surname>Oomens</surname><given-names>L.</given-names></name><name name-style="western"><surname>Tiggelaar</surname><given-names>R.</given-names></name><name name-style="western"><surname>Gardeniers</surname><given-names>H.</given-names></name></person-group><article-title>Performance of Spectrophotometric and Fluorometric DNA Quantification Methods</article-title><source>Analytica</source><year>2022</year><volume>3</volume><fpage>371</fpage><lpage>384</lpage><pub-id pub-id-type="doi">10.3390/analytica3030025</pub-id></element-citation></ref><ref id="B145-molecules-30-03598"><label>145.</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Shen</surname><given-names>C.</given-names></name></person-group><source>Diagnostic Molecular Biology</source><edition>2nd ed.</edition><publisher-name>Elsevier</publisher-name><publisher-loc>Amsterdam, The Netherlands</publisher-loc><year>2023</year></element-citation></ref></ref-list></back><floats-group><fig position="float" id="molecules-30-03598-f001" orientation="portrait"><label>Figure 1</label><caption><p>Structural formula of cytosine.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="molecules-30-03598-g001.jpg"/></fig><fig position="float" id="molecules-30-03598-f002" orientation="portrait"><label>Figure 2</label><caption><p>Structural patterns of cytosine tautomers.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="molecules-30-03598-g002.jpg"/></fig><fig position="float" id="molecules-30-03598-f003" orientation="portrait"><label>Figure 3</label><caption><p>Structural patterns of two forms of cytosine: lactim and lactam [<xref rid="B29-molecules-30-03598" ref-type="bibr">29</xref>].</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="molecules-30-03598-g003.jpg"/></fig><fig position="float" id="molecules-30-03598-f004" orientation="portrait"><label>Figure 4</label><caption><p>Structural of FTC izomers.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="molecules-30-03598-g004.jpg"/></fig><fig position="float" id="molecules-30-03598-f005" orientation="portrait"><label>Figure 5</label><caption><p>Structural of <italic toggle="yes">cidofovir</italic>.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="molecules-30-03598-g005.jpg"/></fig><fig position="float" id="molecules-30-03598-f006" orientation="portrait"><label>Figure 6</label><caption><p>Structures of: (<bold>a</bold>) 4-amino-1-(2-bromobenzyl)-5-(morpholinomethyl)pyrimidin-2(1<italic toggle="yes">H</italic>)-one, (<bold>b</bold>) 4-amino-1-(3-bromobenzyl)-5-(morpholinomethyl)pyrimidin-2(1<italic toggle="yes">H</italic>)-one, and (<bold>c</bold>) 4-amino-1-(4-bromobenzyl)-5-(morpholinomethyl)pyrimidin-2(1<italic toggle="yes">H</italic>)-one.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="molecules-30-03598-g006.jpg"/></fig><fig position="float" id="molecules-30-03598-f007" orientation="portrait"><label>Figure 7</label><caption><p>An example of a chromatogram of the separation of (<bold>a</bold>) 4-amino-1-(2-bromobenzyl)-5-(morpholinomethyl)pyrimidin-2(1<italic toggle="yes">H</italic>)-one, (<bold>b</bold>) 4-amino-1-(3-bromobenzyl)-5-(morpholinomethyl)pyrimidin-2(1<italic toggle="yes">H</italic>)-one, and (<bold>c</bold>) 4-amino-1-(4-bromobenzyl)-5-(morpholinomethyl)pyrimidin-2(1<italic toggle="yes">H</italic>)-one.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="molecules-30-03598-g007.jpg"/></fig><table-wrap position="float" id="molecules-30-03598-t001" orientation="portrait"><object-id pub-id-type="pii">molecules-30-03598-t001_Table 1</object-id><label>Table 1</label><caption><p>Selected cytosine derivatives&#8212;properties and applications [<xref rid="B29-molecules-30-03598" ref-type="bibr">29</xref>,<xref rid="B47-molecules-30-03598" ref-type="bibr">47</xref>,<xref rid="B48-molecules-30-03598" ref-type="bibr">48</xref>,<xref rid="B49-molecules-30-03598" ref-type="bibr">49</xref>].</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Compound<break/>(Abbreviation)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Structure<break/>(Modification)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">pK<sub>a</sub> (&#8776;)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Melting Point</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Solubility in H<sub>2</sub>O (25 &#176;C)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Applications/Remarks</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cytosine (C)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4-aminopyrimidin-2(1<italic toggle="yes">H</italic>)-one</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">~4.6; 12.2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">320&#8211;325 &#176;C <sup>#</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">~7&#8211;8 mg/mL</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DNA/RNA principle; undergoes methylation to 5-mC</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5-Methylcytosine (5-mC)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">cytosine with &#8211;CH<sub>3</sub><break/>in position 5</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4.6; 12.4 (estimate)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">270 &#176;C <sup>#</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">poorly soluble &lt; 5 mg/mL (estimate)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Epigenetic modification of DNA (gene regulation)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5-Fluorocytosine (5-FC)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">cytosine with &#8211;F<break/>in position 5</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">~3.3; ~11</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">295&#8211;297 &#176;C <sup>#</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">15 mg/mL</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Antifungal drug (5-FU prodrug)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5-Azacytosine (in 5-aza-Cyd)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">pyrimidine with N instead <break/>of C5</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">~1.1; 9.2 (for 5-azaC)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&gt;300 &#176;C</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">highly soluble (in nucleoside form)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Component of azacitidine and decitabine drugs (DNA hypomethylation)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cytidine (Cyd)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">nucleoside: cytosine + <break/>ribose &#946;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4.2; ~12.5 (principle)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">230.5 &#176;C <sup>#</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8805;60 mg/mL</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">RNA component; supplement (citicoline)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Deoxycytidine (dCyd)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">nucleoside: cytosine + 2&#8242;-deoxyribose</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4.3; ~12 (principle)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">207&#8211;210 &#176;C <sup>#</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">highly soluble (&#8805;50 mg/mL)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DNA component</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5-Azacytidine <break/>(5-aza-Cyd)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">cytidine analogue with C5 &#8594; N (triazine)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">~229 &#176;C <sup>#</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8805;50 mg/mL (water, unstable)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Anti-cancer drug (Vidaza<sup>&#174;</sup>; MDS, leukaemia)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Decitabine <break/>(5-aza-dCyd)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">deoxycytidine analogue (C5 &#8594; N)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">209 &#176;C <sup>#</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">good solubility in water</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Anti-cancer drug (Dacogen<sup>&#174;</sup>; MDS)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cytarabine <break/>(Ara-C)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1-&#946;-D- arabinofuranosylcytosine</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4.2; 12 (principle)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">212&#8211;213 &#176;C <sup>#</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">~10 mg/mL (water)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cytostatic drug (Ara-C; leukaemia)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Gemcitabine (dFdC)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2&#8242;,2&#8242;-difluorodeoxycytidine</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.6; 12 (principle)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">~168 &#176;C <sup>#</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">~15 mg/mL (water)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cytostatic drug (Gemzar<sup>&#174;</sup>; pancreatic cancer, others)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Lamivudine (3TC)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2&#8242;,3&#8242;-dideoxy-3&#8242;-thiacytidine<break/>(S in the ring)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">~4; 12 (principle)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">160&#8211;162 &#176;C</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8805;20 mg/mL (water)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Antiretroviral drug (NRTI; HIV, HBV)</td></tr></tbody></table><table-wrap-foot><fn><p><sup>#</sup>&#8212;decomposition.</p></fn></table-wrap-foot></table-wrap></floats-group></article></pmc-articleset>